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ABSTRACT 
Healthcare reform and rising costs are driving demand for resource efficiency to facilitate 
better-informed healthcare decisions. Health economics represent an interdisciplinary set of 
tools and concepts to assess the value of everyday decisions, taken in complex healthcare 
settings, to improve healthcare. Many alternative screening methods are currently available, 
but knowledge about costs and the value of potential health gains is inadequate.  
The aims of the thesis were to study the efficiency in the allocation of resources to cervical 
cancer screening of importance for setting priorities: the cost of the most prevalent Human 
Papillomavirus (HPV) related diseases namely cervical dysplasia, cervical cancer and genital 
warts, modeling the cost-effectiveness of cervical cancer screening and exploring knowledge 
of HPV, compliance with screening and its correlates.  
In one study, we estimated the costs from a societal perspective, of the HPV-related diseases 
namely cervical dysplasia, cervical cancer and genital warts. Results provided an estimate of 
€108 million annually showing a significant economic burden on the Swedish welfare system 
appointed by the most prevalent HPV-related diseases attributable to HPV 6, 11, 16 and 18 
infections. 
A Markov model was developed to simulate the natural history of HPV, cervical dysplasia 
and cervical cancer to project the cost-effectiveness of HPV self-sampling within the 
framework of the Swedish organized screening program. Projected results showed that 
screening with conventional cytology up to age 35 and thereafter screening with HPV self-
sampling at home with five-year time intervals between screening opportunities is potentially 
cost-effective compared with either no screening or with current cytology based screening 
practice.  
A decision analytic model was developed to evaluate cost-effectiveness of follow-up with 
HPV triage compared with repeat cytology and immediate colposcopy with biopsy on women 
with index smear diagnosis of ASCUS and LSIL within the Swedish organized screening 
program. Model results showed that immediate colposcopy with biopsy was a cost effective 
follow-up strategy compared with the alternatives. Given the improvement in HPV testing 
techniques at lower costs, HPV triage can become a cost-effective alternative for follow-up of 
minor cytological abnormalities. 
A descriptive study approach was used to assess possible barriers to and facilitators of 
cervical cancer screening by estimating time and travel costs and other direct non-medical 
costs incurred in clinic-based screening, investigating compliance with screening and reasons 
for noncompliance, determining women’s knowledge of human papillomavirus (HPV), and 
investigating correlates of HPV knowledge and compliance with screening. Via self-
administered questionnaires, data were obtained from 1 510 women attending the Swedish 
organized cervical cancer screening program. The study concluded that time and travel costs 
of clinic-based screening can be substantial, may influence overall cost effectiveness of 
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screening programs and constitute barriers to screening. Women with knowledge of HPV and 
who did not take time off work to attend screening were more likely to comply with 
screening.  
Altogether, this thesis has contributed new health economic data on the societal cost of HPV 
related diseases; cervical dysplasia, cervical cancer and genital warts on a national level, and 
patient-level data of indirect costs and other direct non-medical costs for women attending the 
Swedish organized screening program. This together with data on women´s knowledge about 
HPV and their compliance with screening are valuable information for further policy 
decisions on revising the organized screening program. By assessing the impact of HPV-
related diseases in terms of costs is one important step towards efficient allocation of 
resources to reduce the economic burden of these diseases. These data are also valuable 
contribution to economic evaluations, providing information for resource allocation when 
choosing among different screening methods to reduce disease burden, as well as 
contributing to knowledge of compliance with population-based preventive health programs.  
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1 INTRODUCTION 
Cervical cancer (CC) is preventable through screening and vaccination programs, but 
many challenges remain before such programs become fully effective, with the potential to 
fully eradicate the disease using new methods and future technology.  Organized screening 
has already reduced cervical cancer incidence and mortality in Sweden since the program was 
introduced in the 1960s. Worldwide, cervical cancer is still the third most common cancer 
among women, exceeded only by breast cancer and colon cancer; 85% of CC occurs in 
countries that lack organized screening. Statistics show that the incidence of squamous cell 
carcinoma (SCC) is stagnating, while the incidence of adenocarcinoma (ADC) is increasing. 
The newly developed Human Papillomavirus (HPV) test is more sensitive than the 
conventional Pap smear. The introduction of Liquid-based cytology made sample processing 
easier and increased laboratory efficiency, but sensitivity for detecting CIN2+ is still inferior 
compared with Pap smear testing in primary screening. The ongoing debate of whether to 
change from cytology (Pap smear) to HPV testing in primary screening could alter screening 
program protocols: longer screening intervals, triage testing with cytology for HPV-positive 
women and new screening algorithms for management of HPV-positive and cytology-
negative women. Further, availability of HPV self-sampling devices could be offered to 
women who do not comply with the current clinic-based screening program. However, 
questions still remain about how to include all women, including hard-to-reach women, in the 
screening program, what actions to take to reduce potential over-diagnosis and over-treatment 
of regressive disease, and how to reduce adverse outcomes. According to National Board of 
Health and Welfare [Socialstyrelsen] guidelines, decision-makers in Sweden need to 
ascertain both clinical effectiveness and cost-effectiveness before introducing new screening 
programs, or revising the existing population-based screening program. Given that 
compliance with cervical cancer screening is crucial to both the clinical effectiveness and cost 
effectiveness of screening, identification of potential barriers is particularly important. This 
and evaluation of new screening technologies is extremely important. Convention holds that 
cost-effectiveness is assessed from a societal perspective, including all costs imposed on 
society. Depending on the employment circumstances of the individual, screening attendance 
may lead to loss of income. This factor, along with the individually perceived high value for 
time and travel costs and other direct non-medical costs, could deter use of screening 
services. Determining whether costs for time and travel incurred by women to attend 
screening have impact on compliance will strengthen the evidence base for the organized 
screening program. Even though globally HPV is one of the most common sexually 
transmitted infections (STIs), general awareness of HPV is low.  By determining the extent of 
this knowledge gap within the population eligible for screening, invaluable information could 
be made available to public health workers to enable them to deliver a consistent health 
message and to educate the public. 
The aims of the thesis were to study  the efficiency in the allocation of resources to cervical 
cancer screening  of importance for setting priorities: the cost of the most prevalent HPV 
related diseases; cervical dysplasia, cervical cancer and genital warts,  modeling the cost-
effectiveness of cervical cancer screening and exploring knowledge of HPV, compliance with 
screening and its correlates. By doing so, we shall contribute with information to facilitate 
better-informed decisions when revising the organized cervical cancer screening program.  
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2 BACKGROUND 
2.1 CERVICAL CANCER 
Invasive cervical cancer is a malignancy that occurs in the epithelium of the cervix (1). About 
80%-95% of all cervical cancer is classified as squamous cell carcinoma (SCC), followed by 
adenocarcinoma (ADC) (5-20%) (2).  
2.1.1 The cervix 
The cervix, which connects the vagina and the uterus, consists of dense fibromuscular tissue 
and is about 2 cm in diameter and 3 cm long. The cervix consists of two main portions. The 
ectocervix is the outer portion of the cervix that can be visualized from inside the vagina 
during speculum examination. The endocervix is the inner portion of the cervix. The opening 
in the center of the ectocervix, known as the external os, allows passage between the uterus 
and the vagina. The endocervical canal is a tunnel through the cervix, from the external os 
into the uterus. 
 
 Figure1. Cervix and the transformation zone (TZ)              
(Adapted from http://www.cancerresearchuk.org/cancer-help/type/cervical-cancer/about/the-cervix) 
The transformation zone (TZ) is the area between the original and the new squamocolumnar 
junction (SCJ).  The original SCJ remains un-changed until puberty. Post puberty, forming of 
the functional junction occurs and is termed the new SJC.  The area between the original and 
new SCJ occupies by the TZ and expands toward the cervical opening with increasing age 
(3). Cervical cancer arises from the TZ, which is susceptible to oncogenic HPV-induced 
neoplastic transformation (1). Persistent infections with HPV can cause precancerous lesions 
known as cervical intraepithelial neoplasia (CIN). Squamous cell carcinoma (SCC) and 
adenocarcinoma (ADC) is preceded by CIN (4).  
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2.1.2 Natural history of HPV infection, CIN and cervical cancer  
Today it is widely accepted that HPV is the major causal factor in all cervical cancers, which 
likely makes the disease the most common virally-induced cancer (5, 6). HPV infection is 
common among both men and women and is transmitted through sexual activity. HPV 
infection usually clears without treatment, though in some cases the infection persists and 
may progress to precancerous changes (i.e., cervical intraepithelial neoplasia (CIN) that are 
classified according to the proportion of “cervical epithelial cells” showing abnormalities and 
degree of atypia: CIN 1 (mild dysplasia), CIN2 (moderate dysplasia) and CIN 3 (severe 
dysplasia). If undetected and left untreated, CIN3 precancerous lesions may progress to 
invasive cervical cancer (7). Precancerous lesions are amenable to detection through 
screening due to the time of approximately one decade generally required for transformation 
from precancerous lesions into cervical cancer. 
 
Human papillomavirus infection and related diseases 
Human papillomavirus (HPV) is a DNA virus from the papillomavirus family that causes 
productive infections in the keratinocytes of the skin or mucous membranes (8). Most HPV 
infections are asymptomatic.  However, nononcogenic HPV infections (low risk (LR-HPV)) 
such as types 6 and 11 may cause benign papillomas, including warts or squamous cell 
papillomas, while infection with oncogenic HPV (high risk (HR-HPV)) can cause cancers of 
the cervix, vulva, vagina, penis, oropharynx and anus (9).  Retrospective studies have shown 
that almost 100% of cervical cancer cases were HR-HPV-positive. HPV infection is sexually 
transmitted between both men and women and has been insensitive to general improvements 
in medical care and living standards. Therefore, vaccination and organized screening 
programs can prevent HPV epidemics and therefore cancer within a population.   
According to a  study by Söderlund-Strand et al.,2013, 44 146 samples from sexually active 
adolescents were submitted for Chlamydia trachomatis testing in southern Sweden and 
showed that HPV positivity peaked at 54.4% [95% confidence interval (CI), 52.2-56.6] 
among 21-year-old women and at 15.0% (95% CI, 12.4-17.6) among 23-year-old men. 
HPV positivity was 37.8% (95% CI, 37.3-38.3) for women and 11.2% (95% CI, 10.6-11.8) 
for men. The most prevalent types in descending order among women were: HPV 16 
(10.0%; 95% CI, 9.7-10.3) and HPV 51 (6.0%; 95% CI, 5.7-6.3), and among men: HPV 16 
(2.1%; 95% CI, 1.8-2.4) and HPV 51 (1.7%; 95% CI, 1.5-1.9) (10). In another review, 
prevalence among men was reported at 1.3%-72.9% in studies where multiple anatomic 
sites or specimens were evaluated, 56% of which reported > 20% HPV prevalence (11). 
According to a meta-analysis of studies published between 1995 and 2009 that used 
polymerase chain reaction or Hybrid Capture 2 to detect HPV in women with normal 
cytological findings, the most prevalent HR-HPV types in women with normal cytology 
were HPV16 (3.2%), HPV 18 (1.4%), HPV51 (0.9%), HPV31 (0.8) and HPV58 (0.7%), with 
other types representing about 0.6% (12). However, it is important to note that the 
distribution of HPV types may vary between populations and between different assays (12).  
Despite regional variations among different populations, HPV is the most common sexually 
transmitted infection (STI) in the world with a prevalence of 11-12% in women with normal 
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cytology. The majority of HPV infections are transient; 70%-75% clear within 1 year (13) 
and approximately 90% clear within 2 years (14, 15). Among HPV-infected women, 50%-
55% show evidence of an immune response (16). Previous research suggests that the low 
antibody titers resulting from natural HPV infection do not provide full protection against 
future HPV infection (17). Persistent oncogenic HPV infection significantly increases the risk 
for development of cervical precancerous lesions and cervical cancer (18, 19). HPV 
prevalence increases in proportion to severity of lesions, from 12.6% in women with normal 
cytology to 90% in women with CIN grade 3 (CIN3) and invasive cervical cancer (ICC) (12). 
The highest prevalence among women is found within their first years after sexual debut. One 
study reported the prevalence of HPV genotypes 6, 11, 16, and 18 in young women to be 
11.4 %, with the highest rate in the youngest age group (18.1 % in the 11-19 years, 12.5 % 
in the 20-24 years, and 7.0 % in the 25-29 years) (20). One study that used vaginal swab 
collection to examine the association between age and prevalence of HPV regarding low risk 
(LR HPV) and high risk (HR HPV) types among a US sample population (21), showed that 
26.8% (95% CI, 23.3%-30.9%) were positive for any HPV DNA and that HPV prevalence 
increased up to age 20 -24 years and subsequently decreased.  However, the prevalence of 
HPV types 16 and 18 was relatively low. HPV types 6 and 11 (low-risk) and 16 and 18 (high-
risk) were detected in 3.4% of individuals, among whom HPV-6 was detected in 1.3%, HPV 
11 in 0.1%, HPV 16 in 1.5%, and HPV 18 in 0.8%.   
 
 
 
Figure 2. Age and overall prevalence of HPV  
“HPV indicates human papillomavirus; NHANES, National Health and Nutrition Examination 
Survey. Error bars indicate 95% confidence intervals. Both low-risk and high-risk HPV types were 
detected in some females. Low-risk HPV types are defined as HPV type 6, 11, 32, 40, 42, 44, 54, 55, 
61, 62, 64, 71, 72, 74, 81, 83, 84, 87, 89, and 91; and high-risk HPV types as HPV type 16, 18, 26, 
31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, 82, 85, and IS39.”[Adapted from 
Dunne et al., 2000] 
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In 2007, Herzog et al. (3) reported an important difference when comparing distribution of 
oncogenic HPV types in SCC and ADC. Among women with SCC, oncogenic HPV type 16 
(the most prevalent) was found in 50%-60% of cases and oncogenic HPV type 18 was found 
in 10%-20% of cases. For women with ADC, oncogenic HPV type 18 accounts for an 
estimated 40%-60% of cases, while oncogenic HPV type 16 was found in 30%-55% of cases. 
Figure 3. Distribution of the predominant oncogenic HPV types in SCC and ADC  
 
“A, Global distribution of the predominant oncogenic HPV types in cervical SCCs. B, Global 
distribution of the predominant oncogenic HPV types in cervical adenocarcinomas. Fuchsia 
represents type 18; dark pink represents type 16; salmon represents types 45 and 31; yellow 
represents other types.” [Adapted from Herzog et al., 2007.] 
 
Precancerous lesions of the cervix 
Persistent infection with HPV is known to precede cellular neoplasia (8). Precancerous 
lesions precede both SCC and ADC and are divided and classified into cervical neoplasia 
(CIN) grades 1, 2 and 3 based on histological appearance. Degree of severity is based on the 
proportion of atypical cells and architectural disruption, where CIN 1 is mild dysplasia, CIN2 
moderate dysplasia and CIN3 severe dysplasia, or equivalent to cancer in situ (CIS). A 
penetration of the epithelial basement membrane that occurs by atypical cells is defined as 
invasive cervical cancer (22). 
Due to the difficulty in distinguishing among the various CIN grades, the Bethesda system 
was introduced as a supplementary classification system. It is based on cytology, where CIN 
1 is characterized by low grade squamous intraepithelial lesions (LSIL) and where CIN2 and 
3 (CIN2+) are characterized by high-grade squamous intraepithelial lesions (HSIL). The 
Bethesda system also provides nomenclature for the cells that are not able be classified as 
LSIL, such as atypical squamous cells with uncertain significance (ASC-US)  and  atypical 
squamous cells that can´t rule out the possibility of HSIL (ASC-H) (23). The Bethesda 
system also discriminates between atypical glandular cells not otherwise specified (AGC-
NOS), atypical glandular cells that suggest adenocarcinoma in situ (AIS) or cancer (AGC-
neoplastic), and adenocarcinoma in situ (AIS). AIS precedes invasive cervical 
adenocarcinoma and occurs below the TZ and is therefore covered by normal metaplastic or 
dysplastic epithelium. Studies have estimated that the time period required for disease 
progression from AIS and to ADC is 5-13 years (24, 25).  
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There is a cumulative risk of developing ICC or CIS related to severity of dysplasia. If CIN 3 
is left untreated, the risk of developing ICC has been estimated at 30%-50% based on reviews 
of studies on follow-up management of women with abnormal cytology between the years 
1950 and 1990 (7, 26).  However, the majority (88%) of CIN 1 lesions spontaneously regress 
to normal cytology, while only an estimated 10% of CIN1 progresses to CIN3 or worse over 
a 10-year time interval. Progression from CIN 2 to CIN 3 was found to occur in 32% of cases 
over a 10-year period (27).  The proportion of HPV positivity increases with severity of 
cervical lesions. A meta-analysis of 423 PCR-based studies worldwide conducted on a 
population of women with findings ranging from normal to ICC found no significant 
differences in HPV type distribution among women with normal cytology, ASCUS, LSIL 
or CIN1. HPV16 positivity increased with lesion severity, showing a rising trend from 
normal/ASCUS/LSIL/CIN1 (20-28%), through CIN2/HSIL (40/47%) to CIN3/ICC 
(58/63%) (28). A broad range of non-HR-HPV types are commonly detected among women 
with LSIL and HSIL, who demonstrate a high prevalence of multiple infections associated 
with these lesions (29). Given that infections with HPV types 16 and 18 are causally related 
to detected lesions even in the co-presence of other HPV types, the protective impact of 
vaccination against HPV 16 and HPV 18 on cervical lesions can be expected to increase from 
17% in ASC-US, through 49% in HSIL and up to 70% in cervical cancer (28). 
 
2.1.3 Diagnose and treatment 
Invasive cervical cancer is a malignancy arising from the epithelium of the cervix (1). About 
80%-95% of all cervical cancer cases are categorized as squamous cell carcinoma (SCC), 
followed by adenocarcinoma (ADC) (5-20%) (2). The early stages of cervical cancer are 
typically asymptomatic. In later stages, abnormal bleeding is the main symptom of invasive 
cervical cancer. Additional symptoms may occur in advanced stages, including vaginal 
discharge, pelvic or low back pain, and sciatica. Indications of advanced disease include 
bowel and urinary symptoms. Any of these symptoms should prompt further clinical 
examination to obtain a definitive histological diagnosis (30).Women with invasive cervical 
cancer are immediately referred for clinical examination and FIGO staging (available in 
English at http://www.figo.org), the most common classification system worldwide (30).  
 
Treatment of women with diagnosed FIGO stage 
Worldwide, treatment of cervical cancer varies significantly in developed and developing 
countries. This due to scarce health care resources in developing countries, availability of 
surgeons skilled in radical pelvic surgery, and the issue of “fertility-sparing therapy” in 
developed nations. Localized cancer is treated with a combination of radical hysterectomy 
and radiotherapy, while regional and distant cancers are treated with radiotherapy alone (31-
33). Patients with FIGO stage 1a1-1b1 are treated with Wertheim-Meigs radical 
hysterectomy.  Stage 1a1 can be treated by simple hysterectomy or conization since the risk 
of regional lymph node metastasis is very low, while stage 1a2-1b1 is treated with Wertheim-
Meigs radical hysterectomy or trachelectomy with pelvic lymph node dissection, given the 
higher risk of lymph node metastasis. Treatment of patients with FIGO stage II involves 
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combined radio- and chemotherapy. The difference in treatment between FIGO stage II and 
FIGO stage III is the number of brachytherapy treatments and the total dose of radiotherapy 
delivered to the pelvis. In more advanced stages, with a large tumor burden involving the 
parametrium, patients are treated with a higher dose of radiotherapy to the pelvis and fewer 
brachytherapy sessions, compared with large bulky central tumors, which require more 
brachytherapy sessions and a lower total dose of radiotherapy to the pelvis. Treatment of 
patients with FIGO stage III involves radiotherapy and chemotherapy. Palliative treatment 
entails chemotherapy alone. The disseminated disease of FIGO stage IV requires different 
treatment than FIGO stage III, with more chemotherapy and limited radiotherapy delivered 
only to the gross tumor volume. As per national recommendations, patients are followed for 5 
years after treatment, with a total of 13 clinical examinations and 1 MRI after treatment. 
Thereafter, yearly gynecological examinations throughout women’s life are recommended.  
 
Prognosis and survival rates 
According to one study, the presence of lymph node metastases was associated with a worse 
prognosis in ADC than in SCC, but there was no difference in prognosis in the absence of 
lymph node metastases (34). This was further supported by a literature review (35). Another 
study presented contradictory evidence, suggesting lower survival rates among patients with 
ADC in both early and advanced FIGO stages (36). In another study of 1 335 cervical cancer 
cases detected between January 1, 1999 and December 31, 2001, with an 8.5-year follow-up 
period, supporting evidence was found indicating no difference in prognosis between ADC 
and SCC. However, the overall prognosis was better among women detected through 
screening than women who presented with symptoms (37), mainly because screening often 
detects disease in the early stages, whereas symptomatic patients often present in late stages. 
 
 
2.1.4 Quality of life  
 
Survival rate from cervical cancer increasingly depends on early diagnosis and more 
effective treatments. Consequently, the availability of a valid and reliable general health-
related quality of life (HRQL) instrument is important. The HRQL in women diagnosed 
with cervical cancer provides important data for future preventive programs aimed at 
improving women’s health. Quality of life measures generic outcomes, which are 
recommended to help assess the cost effectiveness of new preventive programs. HRQL 
reflects the subjective perceptions and experiences of the individual. Impaired quality of life 
indicates functional limitations and perceived difficulties in everyday life caused by a disease 
or illness. HRQL measurements assess patient health on a scale of 0 to 1, where 0 signifies 
death and 1 perfect health. The EQ-5D instrument summary index score is a standard 
measure for assessing quality of life, which is used to calculate quality adjusted life years 
(QALYs) in economic evaluations (38). Population-based social tariffs (health state 
valuations in the general population) use the EQ-5D instrument to calculate utility weights 
and patient preference. A previous study confirmed that the EQ-5D questionnaire is valid and 
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reliable for the assessment of HRQL in patients with cervical cancer in Taiwan (39). 
Treatment of precancerous and early cervical cancer stages changes patient quality of life. 
Previous studies have focused on the effect of radical treatment for invasive cervical cancer 
on the physical and psychological state of women in late stage disease (40-42). One study 
that addressed the association between HRQL outcomes and survival in a population-based 
cohort of women diagnosed with invasive cervical cancer found that HRQL outcomes, 
especially physical function and mental health dimensions, are associated with survival 
(43). Another study found that the neighborhood context was an influential contributor to 
survival, suggesting the need for future research on the role of ethnic groups, socio-
ecological contexts, stress and medical factors on disease outcomes (44). Further, few 
studies address sexual activity among women diagnosed with early stage cancer (45). 
However, the literature shows that women diagnosed with pre-cancer lesions or cancer 
experienced heightened disease awareness, fear of disease-related death, fear of losing 
reproductive organs and fertility, anxiety over their future family life, social and professional 
life – in other words, the quality of life. 
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2.2 HEALTH ECONOMICS 
 
2.2.1 Health Economics - general issues  
The ability to produce treatments and interventions has increased exponentially with 
introduction of new technologies, while the demand for health care has increased. A 
consequence, health care costs are increasing and puts a strain on limited health care 
resources. Unavoidable choices and trade-offs have to be made since there always will be 
more available technology options that resources will allow. These choices are relevant for 
public decisions about allocation of resources.  Public decisions will have to be made based 
on formal evaluations if the additional health benefits are worth the additional costs implied 
with new technology. Health economics is today a commonly used term in medical and 
scientific literature and policy documents. Over the past decades, there has been a shift from 
´passive funding´ of health care to concerns about resource costs and the health outcomes 
achieved from producing health care.  The relevant question is often; how much money 
should we spend on health care and how do we spend it efficiently? Health economic 
evaluation is a method that has been developed to address this issue and concerned with 
issues relating to the allocation of scarce resources to improve health (46). This fundamental 
change of attitude has led to concerns for both effectiveness and cost-effectiveness of 
innovative technology or interventions, rather than only for efficacy and safety. The 
acceptability for new technology is now more related to the cost and health benefit of the 
incremental improvement to the individual.   
 
Definition of health economic evaluation 
Health economic evaluation can be defined as “the comparative analysis of alternative 
courses of action in terms of both their cost and consequences”(46). The basic mission of any 
health economic evaluation is to identify, measure, value and compare the costs and 
consequences of the various alternatives under consideration in order to determine whether a 
programme offers “good value for money”.  
 
Types of health economic evaluation 
Economic evaluations are normally divided into four different types: cost-minimisation 
analysis, cost-effectiveness analysis, cost-utility analysis and cost-benefit analysis (see Table 
1).  All methods measure costs in monetary terms, but differ in how the health outcomes are 
measured (46-48). In general, if the economic question is whether a treatment or intervention 
is an appropriate use of resources in the specific area of illness, comparison is performed 
between alike treatments and interventions and the outcome measure can be disease specific 
(single outcome). Then a cost-effectiveness analysis will be an appropriate type of evaluation. 
When there is occurrence of multiple outcomes, either a choice of one outcome measure or an 
index should preferably be constructed.  For example, outcomes for interventions for cervical 
cancer can be survival, remissions, adverse events, quality of life, etc. If the economic 
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question is whether a treatment or intervention is considered an appropriate investment when 
considering all diseases, the comparison will be with treatments and interventions in other 
diseases and outcome measures are generic such as quality-adjusted life year (QALY), an 
outcome that combines survival and quality of life. Then, this would be a cost-utility analysis 
which is considered a specific type of cost-effectiveness analysis. However, the most 
important question is if there is data on clinical evidence existing for the alternative 
treatments or interventions. The effectiveness data will assess the quality of the economic 
evaluation. In Table 1, a summary is presented of effectiveness measures used in the different 
types of economic evaluations with indication on what type of question to address. Also, each 
of these types is further explained below. Further, the cost-of-illness study (COI), a form of 
economic analysis which attempts to estimate the economic burden placed up on society for a 
disease is also discussed further below.   
 
Table 1. Usability and measure of effect in different types of economic evaluations 
Analysis Effectiveness Usability 
Cost-minimization analysis The effects of alternatives are 
identical and therefore not 
measured. 
Comparison of costs of 
treatment(s)/intervention(s) 
within the same disease 
Cost-effectiveness analysis 
(CEA) 
One disease specific measure 
(e.g. relapses avoided), disease 
free time, life years saved or an 
index with multiple measures  
Comparison of 
treatment(s)/intervention(s) 
within the same disease 
Cost-utility analysis (CUA) Summary measure combining 
survival and quality of life (e.g. 
quality of life years (QALYs)) 
Comparison of 
treatment(s)/intervention(s) for 
different diseases 
Cost-benefit analysis (CBA) Effectiveness expressed as 
monetary benefit (e.g. 
willingness to pay (WTP)) 
Comparison of investment in 
the health sector with 
investments in other sectors 
(e.g. road safety or education) 
[Adapted from Kobelt 2002 (49)] 
Cost-minimization analysis compares interventions based on cost alone and is used when 
alternative interventions have equivalent health outcomes. The least costly alternative then 
becomes the preferred approach.  
Cost-effectiveness analysis (CEA) assesses both the costs (C) and effects (E) of alternative 
interventions measured in one-dimensional units, such as life years gained (LYG) or an index 
with multiple measures. Regarding decisions about resource allocation, the relevant measure 
in economic evaluation is the incremental cost effectiveness ratio (ICER) (see Box 1). ICER 
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is defined as the ratio of the incremental difference in total cost to the incremental difference 
in effectiveness when comparing alternatives. For example, if the question is whether to 
replace an existing treatment or intervention with a new one which is more effective but also 
more costly, then information about the additional recourses spent to achieve additional 
benefit is of importance for a decision-maker.                 
 
Box 1. Definition of the incremental cost-effectiveness ratio (ICER) 
 
 
 
 
 
 
 
 
ICER can be viewed as the incremental cost of producing extra health benefits from one 
alternative compared with the next most effective alternative intervention. For example, to 
determine cost-effectiveness, the ICER is a useful tool to help health planners take decisions 
on screening programmes when working within budgetary constraints; for example, they may 
be interested in maximizing the number of cases detected and knowing the incremental cost 
per case detected would therefore be relevant. However, “life years gained” might be a better 
outcome measure to use in a CEA of cancer screening programmes where the aim is to 
prevent morbidity and reduce mortality. 
A cost-utility analysis (CUA) enables comparisons across different disease areas of costs 
related to a generic outcome (i.e. multidimensional consequences) (48). A common utility 
index that weighs the consequences of survival and quality of life is the quality of life year 
(QALY), a measure of disease burden including both the quality and the quantity of life lived 
(50). QALYs are calculated by multiplying number of life years gained by a utility value 
representing the health status of the individual. Value of utility ranges from 0 (i.e. dead) to 1 
(i.e. perfect health) (see Figure 4). Rating scale, standard gamble or time-trade-off are used to 
measure utility values.  The EuroQol five dimensions questionnaire (EQ-5D) is the most 
commonly used rating scale (50).  
                 [ Cost (B) – Cost (A) ]             Difference in Cost 
                 [ Effect (B) – Effect (A) ]        Difference in Effect 
                
                Where B is more effective and more costly than A. 
                (If B is more effective and less costly than A, it  
                dominates A and the ICER is not calculated.) 
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Figure 4. Quality-adjusted life years  
 
“The area beneath the “without intervention” curve (area A) represents the number of QALYs 
associated with the control group. The area beneath the “with intervention” curve (area A plus area 
B) represents the number of QALYs associated with the intervention group. Area B represents the 
QALY gain associated with the intervention.”[Adapted from www.acnr.uk] 
 
Cost-benefit analysis (CBA) expresses both cost and outcomes in monetary terms. A 
potential use is for comparing investments in the healthcare sector with investments in other 
sectors (e.g. road safety or education). The benefits are preferably measures by the 
willingness to pay (WTP). When value of the total benefit outcomes from a health care 
programme exceed the values of the total costs it is considered “good value for money”(48).  
 
 
2.2.2 Decision rules of cost-effectiveness analysis 
 
The cost-effectiveness plane (CE plane) forms the basis of several key studies presented in 
medical decision-making literature.  It is an important tool used in cost-effectiveness analysis, 
and applied widely in the healthcare industry. The CE plane aims to illustrate differences in 
costs and effects between different chosen strategies (e.g. medical or no medical 
interventions, treatments, or combination of interventions and treatments). To make informed 
decisions regarding allocation of scares resources, the CE plane visually presents the relative 
value of strategies, and informs its viewer to evaluate multiple strategies. Four different 
groups of results can occur when comparing two alternative interventions, as can be 
illustrated in a cost-effectiveness plane (Figure 5). With a reference strategy placed at the 
graphs, a cost-effectiveness analysis (CEA) can plot the incremental costs (y-axis) and effects 
(x-axis) of two alternative strategies, relative to each other.  The area above the horizontal is 
cost-increasing, and to the right of the vertical, more effective with improved health. When a 
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new strategy is more effective and increases costs, an incremental cost-effectiveness ratio 
(ICER) is calculated.  
 
Figure 5. The cost-effectiveness plane (CE-plane) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
With a reference strategy placed at the graphs, a cost-effectiveness analysis (CEA) can plot the 
incremental costs (y-axis) and effects (x-axis) of two alternative strategies, relative to each other.  
When a new strategy is more effective and increases costs, an incremental cost-effectiveness ratio 
(ICER) is calculated.[Adapted from Drummond (46).] 
 
The ICER should be valued by the decision-maker. An optimal choice depend on the 
willingness-to pay (WTP) for an additional unit of effect. If there is a defined WTP, choice of 
strategy depend on if the calculated ICER is below this threshold value. However, to 
determine which healthcare programme that is cost-effective, we need to determine how 
much society is willing to pay for a QALY (or for another effectiveness measure used in the 
CEA). Without information about this price per unit of health gain, a CEA provides no 
information on whether or not to implement a programme. This implies that the cost per 
QALY gained must be below a threshold value that reflects how much society is willing to 
spend to gain one QALY. The commonly used threshold value for cost-effectiveness usually 
ranges between USD 50,000 and USD 100, 000. Studies that estimate the social value of a 
QALY derived from estimates of the value of a statistical life (VSL) usually suggest even 
higher values (51, 52).   In developing countries, the WHO Commission on 
Macroeconomics and Health suggests that interventions with an ICER costing less than 
three times the gross domestic product (GDP) per capita represent good value for money 
spent to eliminate each disability-adjusted life year (DALY) (53). Another way for national 
Less effective More effective 
Effect   
Cost 
Cost- 
saving 
Cost- 
increasing 
WTP 
ICER= 
Dominant 
Dominated 
 
[Cost difference]              
[Effect difference] 
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governments to set threshold values is to base them on previous reimbursement decisions 
and guidelines (54). 
 
2.2.3 Data for health economic evaluations 
Costs are assessed in the same way for all types of health economic evaluations. First, 
identify the relevant resources used, regardless of whether they can be measured. Second, 
quantify the resources in physical units (i.e., number of clinic visits, hospital days, medical 
procedures, tests, etc.). Third, set a value for the resources used at their opportunity costs; for 
example, use the gross wage rate to value the time of patients or professionals. 
Recommended alternatives include the “micro costing” approach (although the need for 
accuracy in calculating costs must be weighed against the expense of collecting the necessary 
information), or the “macro costing” approach where costs are based on aggregate measures 
of resource use (i.e., a whole procedure for a medical event).  
 
Perspective 
 
The choice of perspective (e.g. patient, individual, employer, hospital, government, insurance 
company, private agency, and society) for the economic evaluation determines which costs to 
include in the analysis. To inform efficient  allocation of health care resources, economic 
evaluations should be based on a societal perspective (55). A societal perspective implies not 
only that the costs that refer to the health care system should be included but also costs of 
informal care, loss of production, and costs of added years of life. If the economic evaluation 
is based on a restricted perspective (e.g. a health care perspective) this would not necessary 
lead to an efficient use of resources from a societal perspective. Moreover, diseases (e.g. 
cervical cancer) have a broad impact on a range of personal dimensions (e.g., patient health, 
quality of life, ability to work, social and sexual relations, and income). Furthermore, a 
narrow perspective makes comparing results difficult due to differences in health care from 
one country to the next (46). 
 
Discounting 
Often, economical analyses cover a long time period and costs and health effects do often not 
occur at the same time. For direct comparison treatments(s)/intervention(s) in different time 
periods, discounting should be made. Discounting is not a correction of inflation, instead it 
reflects time preference and the wish to have benefits earlier rather than later, and the returns 
that could have been gained if health recourses were invested somewhere else. Although, 
different opinions exist on whether both costs and effects should be discounted and whether 
health effects should be discounted using a lower rate, the usual recommendation is that costs 
and health effects in the base case analysis are discounted at the same rate. In a sensitivity 
analysis a lower discount rate for health effects should be used.   Usually costs and health 
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effects are discounted with the same rate (3% or 5%)  and in a complementary analysis health 
effects are discounted at 0% (46).  
 
Future cost (costs of added years of life) 
The most common practice in cost-effectiveness analysis is to include future medical costs 
only for “related” diseases and excluding future medical costs for “unrelated” diseases and 
future non-medical costs. However, Meltzer (1997) that bases the cost-effectiveness analysis 
on the theory of welfare economics concludes that all future costs (medical and non-medical) 
should be included in a cost-effectiveness analysis. An intervention that increases survival 
implies changes in medical and non-medical consumption and may also result in changes in 
production that should be taken into account in a cost-effectiveness analysis from a societal 
perspective. Thus, to reflect the societal cost perspective the difference between total 
consumption (medical and non-medical) and production of added years of life should be 
included in a cost-effectiveness analysis (56). The difference between total consumption and 
production in life-years gained depends on the age. Individuals who are not part of the  
labor force consume more resources than they produce, while those in the labor force produce  
more than they consume. One consequence of not including costs of added years of life  
is that interventions are favored that extend life over those that improve  
quality of life for the elderly, while the opposite is the case for younger (56-59). 
 
Resource type and valuation 
International comparability between economic analyses may contribute to rational decision-
making in healthcare policy. Although estimates should preferably be comparable between 
countries, outcome results may be confounded by variations in methodology, data sources, 
valuation of production losses, and social security arrangements (60). When considering 
costs, they are divided into direct and indirect costs (46). Direct costs include direct medical 
and direct non-medical costs. Direct medical costs include inpatient (hospital) and outpatient 
care (e.g. visit to a medical professional at an outpatient clinic), medical procedures, tests, 
medical devices and home health services. Direct non-medical costs are unrelated to health 
care and include costs for travel, transportation, adaptation, investments, assistance, and 
unpaid care by family, friends or relatives.  Indirect costs relate to productivity loss to society 
due to healthcare programs or illnesses (e.g. sick leave, reduced productivity, early 
retirement).  Individuals who are not part of the labor force have no indirect costs. Estimates 
of indirect costs often influence the outcome of economic evaluations. Another 
consideration is the leisure time lost by patients due to use of health care services (i.e. unpaid 
activities)and valuation of these (61). Intangible costs include such consequences (e.g., pain, 
psychological suffering, and change in social sexual functioning or sexual functioning caused 
by disease) that are difficult to measure and value; they are rarely included in economic 
evaluation, but are sometimes reflected in the denominator of the ICER.   
Important practices when estimating costs include identifying relevant resources, quantifying 
these resources and assessing the costs of the quantified resources. Economic theory states 
that a resource should be priced based on its opportunity costs (i.e., the value of the benefits 
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forgone when the resource is not available as the best alternative for use) (46), though market 
price, which is often available, is more often used. When assessing the value of informal care 
(i.e., care provided by family, relatives or friends), income lost is often used and opportunity 
cost can be estimated using the gross wage rate of caregivers (48), though informal care is 
often provided during leisure time. The opportunity cost of leisure time has been suggested to 
be valued at null, or based on average earnings, overtime earnings or a rate reflecting the take 
home pay. Alternatively, informal care can be valued using the replacement cost method (i.e., 
at market value for caregivers) (55, 62). Another approach used to value changes in 
productivity (i.e., indirect costs) is the human-capital approach, which estimates the value of 
lost production for those employed based on gross earnings (63). However, this approach has 
been criticized since it does not take into account replacement of the absent worker, which 
reduces productivity loss.  Therefore, the friction-cost method, which only considers loss of 
production due to the absent employee, should be used in assessments until the initial level of 
productivity can be restored (64). However, criticism has been aimed at this approach 
because it is based on assumptions. A more recent approach holds that the value of absence 
may affect team productivity and give rise to higher production loss (65).  
 
2.2.4 Cost of illness 
A cost-of-illness study is a descriptive type of analysis which estimates disease-specific costs, 
and provides information on the maximum potential savings that could be done if a disease 
were to be eradicated. Cost-of-illness studies are most commonly based on a top-down or 
bottom-up approach (66). A top-down approach considers the total national costs for a 
disease, divided among different types of disease after diagnosis of the principal disease. 
When using a bottom-up approach, data are collected from the study target population and 
estimates are extrapolated to make them representative for an entire population by using 
national prevalence estimates. One benefit of the top-down approach is that extrapolation is 
unnecessary, thereby avoiding the risk of duplication of costs. The disadvantage is that 
diagnoses may not be reported, or may be misclassified, which leads to missing costs in the 
national registries. However, costs for social services, unpaid help and net cash outlays are 
not taken into consideration, though mortality and disability pension are recorded by main 
diagnosis in the national registries. Statistics regarding short-term sick leave and unpaid time 
off work usually are not recorded. Cost-of-illness studies are performed using either the 
prevalence or incidence method. The prevalence-based approach considers those costs 
incurred over a given time period, usually one year, without regard for date of onset. The 
incidence-based approach considers the costs for a disease that develops for the first time in a 
given time period. Future costs and production losses are estimated over a life time and 
calculated in current values. Incidence-based studies are suitable for evaluating preventive 
measures when calculating the economic benefits of reducing the number of new cases (67). 
If cost control is the major concern, the prevalence-based approach is preferable, since the 
main resources used and the indirect costs are identified and can be used in the effort to 
achieve savings.  
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2.2.5 Decision-analytic modeling 
When there is uncertainty about a decision for which information is available to serve as a 
base, decision-analytic modeling is commonly used. The purpose of modeling is to: (1) 
simplify a complex situation by isolating critical study aspects; (2) integrate data from 
various sources (i.e., economic, clinical or epidemiological data) and (3) project simulated 
outcomes from alternative actions beyond the time frame of the data in order to understand 
long-term implications (63, 68). One approach is the within trial analysis using patient-level 
information where analysis and data collection concerning costs and effects are carried out 
simultaneously with the clinical trial. However, unforeseen consequences may arise 
following the clinical trial period; in health economic evaluation, all relevant costs and effects 
need to be considered, regardless of occurrence in time. Furthermore, the clinical trial target 
population is never fully representative of the actual target population.  Therefore, decision-
analytic simulation modeling can be used when estimating the cost-effectiveness of an 
intervention. Various techniques include: decision-tree models, Markov cohort models, 
individual-based simulation models and discrete event simulation (DES) models. A decision 
tree model calculates costs and health outcome (e.g., probabilities and payoffs) between 
alternative interventions and is suitable for short-term analyses or when outcomes are limited. 
See further example in Figure 6 below.   
Markov models are discrete health state-transition models based on continuous risk over time 
and are commonly used for interventions characterized by a recurrence of events, such as 
screening programs for a specific disease (e.g., cervical cancer or colorectal cancer)(68). It is 
important to keep in mind that no memory assumption is made and that future events depend 
only on the current state (69).  When the model’s probabilities, costs and effects need to be 
changed following an event over time, an individual-based simulation model is appropriate. 
The possibility of tracking the history of the model pathway can be used to provide 
information when applying probabilities, costs and effects in the simulation model. One type 
of individual simulation model is the discrete event simulation (DES) model that focuses on 
events rather than health states, as in the Markov model simulation. In a DES model, 
individuals are followed over time and at discrete points in time, events occur according to a 
queue of events; an individual can be in multiple activities at the same time. DES is also 
particularly well-suited to diseases such as cancer, where the key factor in the disease 
epidemiology is the time when an event occurs (63). For example, HPV vaccination should 
be given prior to sexual debut (girls and boys at age 10-12) to have the best possible effect 
and avoid cervical cancer later in life. 
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Figure 6. Decision tree 
 
Figure X. Decision tree 
 
 
 
 
 
 
 
 
       Decision node                        Chance node                        End node 
The cost-effectiveness of treatment/intervention compared with no treatment/intervention would be 
estimated by comparing the two strategies. In this example of a decision tree, a decision is made to 
attend or not to attend the screening program that reduces the risk of CIN2+ and consequently 
cervical cancer (decision node). In both cases, women can have CIN, but the probability (chance 
node) in the intervention group (p1) is lower than in the no screening group (p2). Consequently, cost 
of screening for cervical cancer is lower in the intervention group since less women develop cervical 
cancer based on the assumption that they are treated in the same way in both groups when cervical 
cancer are detected.  
 
Uncertainty 
Uncertainty always occurs in model-based cost-effectiveness analyses and can be categorized 
as: methodological, modeling, transferability, generalizability and parameter uncertainty 
(70).  Methodological uncertainty occurs when comparing outcomes from studies that are 
based on different methodology and is often handled using sensitivity analysis and a 
reference case. Modeling uncertainty is related to the development of the model and dealt 
with using sensitivity analysis or changing the model structure. When applying results from 
one model to other settings, transferability and generalizability uncertainty occurs. Most 
commonly discussed is parameter uncertainty, which refers to the uncertainty concerning the 
input data of the model and is related to the limitations of the data used in the model. Here 
too, sensitivity analysis is an important tool to validate the results of the cost-effectiveness 
analysis. A one-way sensitivity analysis or a probabilistic analysis may be used to address 
uncertainty by varying one or several parameters in the model within a given range and by 
doing Monte Carlo simulation.   
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2.3 KEY FACTORS AFFECTING THE COST-EFFECTIVENESS OF CERVICAL 
CANCER SCREENING PROGRAMS 
 
To present an overview of past and recent health economic studies of cervical cancer and key 
factors that affect the cost-effectiveness of screening programs, a literature search was 
conducted using PubMed, MedLine and the Health Economic Evaluation Database (HEED) 
to find relevant publications. This chapter outlines key factors that have impact on the cost-
effectiveness of cervical cancer screening programs including burden of cervical dysplasia 
and cervical cancer, morbidity and mortality and different types of screening tests, treatments 
and adverse events. A discussion about the potential effect of HPV vaccine on screening, as 
well as issues concerning epidemiology and cost-effectiveness are included.   Other factors 
affecting the cost-effectiveness of a screening program is access to screening, population 
coverage, knowledge and acceptability among the population which is presented in next 
chapter; 2.4“Barriers to and facilitators of compliance with cervical cancer screening”.  
 
2.3.1 Disease burden 
Worldwide, cervical cancer is the third most common cancer among women, only exceeded 
by breast and colorectal cancer, with an estimated 530 000 new cases and 275 000 cancer 
deaths in 2008 (71). More than 85% of the global burden occurs in developing countries 
where no prevention program is offered, including organized screening programs, vaccination 
or adequate treatment.  The highest risk is found in Eastern or Western Africa, where age-
standardized rates are above 30/100 000, while the lowest risk is found in Western Asia, 
North America and Australia, where age-standardized rates are below 6/100 000.  
 
Figure 7. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. 
Worldwide cervical cancer, map presenting estimated age-standardized (world standards) incidence 
per 100 000 in 2008 (all ages). [Adapted from GLOBOCAN 2008(72)]. 
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Criteria for implementing a screening program 
In 1968 the World Health Organization established a list of general criteria for screening for 
any disease (73):  
Box 2. General criteria for implementing screening  
(1) The condition should be an important health problem.  
(2) There should be accepted treatments for patients with recognized disease.  
(3) Facilities for diagnosis and treatment should be available.  
(4) There should be a recognizable latent or early symptomatic stage.  
(5) There should be a suitable test or examination.  
(6) The test should be accepted by the population. 
(7) The natural history of the condition, including from latent to declared disease, should be 
adequately understood. 
(8) There should be an agreed policy on what patients to treat.  
(9) The cost of case-finding (including diagnosis and treatment of patients diagnosed) should 
be economically balanced in relation to possible expenditure on medical care as a whole.  
(10) Case-finding should be a continuous process and not a “once and for all” project. 
   
In countries with organized screening programs, incidence and mortality have been 
dramatically reduced due to the ability to identify precancerous lesions and to treat early 
stages of cervical cancer (74, 75). In Sweden,  there has been a 67% reduction in the 
incidence of cervical cancer, although this trend has stagnated somewhat in recent years (76). 
According to 2012 statistics from the Swedish National Board of Health and Welfare, the 
decline in incidence has gone from 20 cervical cancer cases per 100 000 women in 1965 to 
around 7/100 000 in the late 1990s. In the 35-39 year age group, there was a 66% reduction in 
incidence from 46.0 to 15.5 per 100 000 women from 1958 and 2004. In the 70-74 year age 
group, there was a 42% reduction (27.0-11.4 per 100 000 women) during the same period. 
According to the Swedish Cause of Death Register, the age-standardized mortality rate was 
7.7 per 100 0000 women 1959 and 2.8  2004 (77).  Despite the decline in the incidence of 
squamous cell cervical carcinoma over the same time period following the introduction of 
organized Pap smear screening, the incidence of adenocarcinoma increased annually in 
Europe by 0.5 to >3%, especially among women below age 40 (78-82).  The Pap smear has 
proven to be less effective in detecting ADC, while more effective in detecting SCC, 
especially among women <40 years (83, 84).  According to registry-based reports, 20% of 
Swedish women do not participate in cervical cancer screening (85) and it is recognized that 
they are at greater risk of developing cervical cancer (1, 37, 74, 85, 86).  
 
 
2.3.2 Screening for cervical cancer 
Today, it is known that persistent infection with oncogenic human papillomavirus (HPV) 
precedes cellular neoplasia (8). Knowledge about the natural history of the disease has led to 
the development of  cervical cancer prevention methods, including screening with cytology 
and, more recently, HPV testing and HPV vaccination. Until recently, no randomized-
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controlled trials (RCTs) have shown that screening, including treatment of CIN, reduces 
cervical cancer incidence and mortality (87). The effects of cervical cancer screening have 
been assessed using studies of observational that have shown a rapid decline in the incidence 
of cervical cancer following implementation of organized screening programs. A 2009 RCT 
from India that compared conventional cytology screening using either Pap smear or HPV 
testing with no offered screening confirmed that screening with HPV tests was an effective 
prevention method for reducing both the incidence and mortality of cervical cancer (88). 
Cervical cancer screening programs vary by country and setting (89). 
 
Organized screening program in Sweden 
Sweden introduced organized screening in the early 1960s and the program had become 
common practice by 1974. The screening program resulted in a significant reduction in the 
incidence of SCC, while the impact on incidence of ADC was more modest (82). A 
comparison of the screened and unscreened populations showed a difference in the cancer 
detection rate in the early stages (55% vs. 17%) and the percentage of advanced stages FIGO 
III and FIGO IV declined from 29% to 21% and mortality also declined due to the early 
detection of CIN and treatment of precancerous lesions, as well as early stage detection (37). 
In Sweden, all women aged 23-49 are offered cytology testing (either Pap smear or Liquid-
based cytology (LBC) at a local outpatient clinic every three years and women aged 50-60 
are called every five years. Abnormalities are followed up immediately using colposcopy 
with biopsy, as recommended by WHO guidelines (available at www.sfog.se). Today, 
several trials have shown that HPV testing is highly sensitive, but less specific (90). Also, 
large population-based randomized controlled trials have shown that primary HPV testing is 
more effective than conventional cytology in reducing both the incidence and mortality of 
cervical cancer (91).  The risk of detecting CIN3 or cancer is lower 5 years after an HPV-
negative test than 3 years after a negative Pap test; HPV DNA has a higher prospective 
negative predictive value (92). However, the optimal screening interval has yet to be 
determined (93). Because of these advantages, the Swedish screening program is currently 
transitioning from primary screening with Pap smears to primary screening with HPV testing. 
Consequently, existing screening protocols are being modified and new follow-up procedures 
for HPV-positive women are being developed in countries with organized screening.  
 
Clinic-based screening 
Pap smear 
The WHO recommends Pap smear screening, first developed by Dr. Papanicolaou in 1941. 
Precancerous lesions develop in the TZ, from which a cytology sample is taken.  Exfoliating 
cells are collected from the ectocervix by using a spatula.  Exfoliating cells are collected by 
using a brush from the endocervix. The samples thereafter are directly smeared onto a glass 
slide and fixed in 95% ethyl alcohol to prevent air-drying. The glass slide is examined under 
a microscope. Adequate samples contain both metaplastic squamous cells and endocervical 
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cells. European guidelines recommend three methods for sampling (74). However, a 
combination of Cytobrush and spatula is preferred (94, 95). The Pap smear has limited 
sensitivity for histologically confirmed CIN2+ (50%-70%) (90, 96). A systematic review 
showed highly variable sensitivity ranging from 30%-87% with specificity ranging from 
86%-100% (97). The overall low sensitivity can be improved with repeat testing 3 to 5 years 
later as part of the screening program. Pap smear is less protective against development of 
ADC than SCC. An Italian study found that the odds ratio for developing ADC among 
women who had undergone Pap testing within 3 years of the index date was 0.65 (95% 
confidence interval (CI) 0.26-1.64), while the corresponding figure for SCC was 0.15 (95% 
CI 0.07-0.31). The protective effect was shorter in duration for women under age 40 than 
for older women (83). 
 
Liquid based cytology 
Liquid-based cytology (LBC) was developed to improve the quality of conventional Pap 
smears and introduced in the 1990s.  The collection method is the same as for Pap smears. 
The sample is immersed and rinsed in a vial containing collection fluid and then processed. 
Available tests are ThinPrep (Cytec Corp. Marlborough, MA, USA) and SurePath (BD, 
Franklin Lakes, NJ, USA). The ThinPrep method was approved by the United States Food 
and Drug Administration (US FDA) in 1996. Most importantly, LBC enables supplementary 
sampling of HPV DNA (e.g. HPV reflex testing), which increases the efficiency of cytology 
screening. Whether LBC is more accurate than the Pap smear remains to be seen. A study 
comparing Pap smears with LBC found that the ThinPrep method was somewhat more 
sensitive (66% vs. 47%). Similar results were found in a randomized controlled trial (RTC) 
(98).  However, a meta-analysis showed that LBC and Pap smear had similar accuracy (99). 
In addition, a Swedish study found no significant difference in accuracy between LBC with 
HPV DNA testing (reflex method) and conventional Pap smear (100).  
 
HPV-tests  
Today, all HPV testing is based on detection of HPV nucleic acids, including   
deoxyribonucleic acid (DNA) and   ribonucleic acid (RNA), in clinical samples (101). One 
review assessed 125 commercially available HPV tests (102) and an increase in the number 
of tests is expected due to the wide range of clinical applications. HPV testing displays higher 
sensitivity than cytology testing, but lower specificity for detection of histologically 
confirmed CIN2+.  The higher negative predictive value (NPV) of HPV testing provides 
additional assurance for HPV-negative women that they do not have any significant 
precancerous lesions. US FDA-approved tests include: Hybrid Capture 2 (HC2) (Digene 
Corporation, Gaithersburg, Maryland, USA), Cervista HPV HR (Hologic, WI, USA), 
Cervista HPV 16/18 (Hologic Inc., Bedford, MMMA, USA) and Cobas 4800 HPV test. 
Cobas was evaluated in the ATHENA study(Addressing THE Need for Advanced HPV 
Diagnostics study) (103).Only one RNA-based assay is available, the APRIMA HPV assay 
(formerly GenProb Inc., San Diego, CA, USA) (101). The Hybrid Capture 2 HPV DNA test 
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is the most frequently used HPV test worldwide.  The HC2 detects 12 HR-HPV types (IARC-
2009) and HPV68. It was FDA-approved in 2003 for triage of women with minor cytological 
abnormalities, as well as for triage in women over age 30, and has been shown to perform 
well clinically in international RCTs and cohort studies. Other HPV tests need to demonstrate 
similar clinical performance before being recommended for use in clinical studies (102).  
The feasibility of HPV testing for use in primary screening has been subject to discussion 
mainly because of its low specificity when used as a single HPV test, especially among 
young women, where HPV testing leads to over-diagnosis of regressive CIN2 (104). One 
large review showed that this method was more sensitive than cytology for detecting CIN2+ 
(96.1% vs. 53.0%), but less specific (90.7% vs. 96.3%); specificity of both tests increased 
with age (105).  However, cytology was substantially more sensitive among women over 
the age of 50 than among younger women (79.3% vs. 59.6%) (105).One study showed that 
women found to be HPV-negative at baseline had a significantly higher NPV for progression 
to CIN3 or worse than women found to be cytology-negative at baseline (92).HPV testing in 
primary screening and cytology as triage showed higher sensitivity in detecting CIN3 or 
worse than primary cytology alone (106). Apart from the feasibility of HPV testing for 
primary screening and especially among women over age 30, HPV testing can also be 
considered useful for triage to identify those women with minor cytological abnormalities 
who are truly at risk of progressing to HSIL and need further follow-up with gynecological 
examination. Another application involves follow-up of women previously treated for CIN to 
predict further risk of developing cervical cancer (107, 108).  
 
Home-based screening 
Self-sampling combined with HR-HPV testing is a rather new approach to screening. HPV 
testing is performed in the privacy of the home as a feasible alternative for non-participants in 
clinic-based screening programs, hard-to-reach women and women reluctant to undergo 
vaginal examination (109, 110).  Overall, it could potentially increase the overall 
participation rate of organized screening (111). A response rate of 40% was found in a 
Swedish study of almost 3000 women aged 30-58 who had not attended screening for > 6 
years. They were offered self-sampling at home (Qvintip) and asked  to send the vaginal 
fluid sample to a laboratory for hr HPV analysis (HC2) (110).  The study found a high 
prevalence of HR-HPV, ranging from 11.1% in women aged 30-39 to 2.9% in women > 
age 50. Histological CIN2+ was detected in approximately 43% of the women with 
persistent HPV infection (2.0% of the total number of responders). By comparison, the 
sensitivity of a single Pap smear for detection of CIN2+ was 52.6%. A study was conducted 
on post-menopausal women (age 55-76) who were offered both HR HPV testing and 
conventional Pap smear as part of the gynecological screening program from 2008-2010. 
The results found HR-HPV in 6.2% (95% CI 5.2-7.3%) of these women, 22% (95% CI 14-
32%) of whom had CIN2+; most of the CIN2+ lesions in post-menopausal women were not 
detected by a single Pap smear (112).  
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A meta-analysis of almost 40 studies with data from approximately 150 000 women showed 
that average sensitivity for detection of CIN2 was 76% (95% CI 69%-82%) and for CIN3 
84% (95% CI 72%-92%), while specificity for CIN2+ was 86% (95% CI 83%-89%) and for 
CIN3+ 87% (95% CI 84-90) (113). Samples taken by a clinician showed overall higher 
accuracy (pooled sensitivity and specificity) than self-sampling performed by the women 
themselves.  Self-sampling combined with HPV testing using signal-based assays was both 
less sensitive and less specific than sampling by a clinician. However, some PCR-based 
(polymerase chain reaction, a technology that selectively amplifies a target sequence of 
DNA) HPV tests showed similar sensitivity between samples collected by the women 
themselves and those taken by a clinician. Therefore, the meta-analysis concluded that 
organized screening programs that use signal-based assays (cell-based assays) should rely 
on samples collected by a clinician. However, some PCR-based HPV tests were considered 
after thorough pilot studies to assess feasibility. Study II, in present thesis, was modeled on 
data from a study examining HR-HPV among women aged 30-65, using PCR-based HPV 
tests. The women used a “Viba-brush (Rovers Medical Devices, B.V., Oss, the Netherlands)” 
to collect vaginal cells, which were then applied to an indicating “FTATM  Elute Micro Card 
(GE Healthcare, Chalfont St Giles, UK)”, and subsequently mailed for HPV analysis using an 
“RT-PCR capable of detecting HR-HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 
59” (114-116). This study found HR-HPV in 6.6% of the women, 89% of whom performed 
follow-up examination on average 2.7 months after the initial test; 59% of these women 
were HR-HPV-positive in the follow-up test (114). Among the women with a positive 
initial HR HPV test, 23% were HR-HPV-positive (95% CI 18-30%), and 41% (95% CI 31-
51%) of women who repeated the test almost 3 months later were HR-HPV-positive. 
Repeat HR HPV testing at short intervals increased specificity for detection of CIN2+ 
lesions from about 94.2% to 97.8%. 
 
 
2.3.3 Follow up, treatment for CIN and adverse events 
Colposcopy is used for follow-up of abnormal cytology to identify diseased tissue for 
sampling biopsies to provide histopathological confirmation of cytology results. Some studies 
have questioned the accuracy of colposcopically-directed punch biopsies. According to one 
meta-analysis the threshold for distinguishing between a normal cervix and LSIL, compared 
with HSIL and cancer, showed an average weighted sensitivity of 85% and average 
weighted specificity of 69% (117). One important factor for high sensitivity was a highly 
skilled colposcopist taking random and multiple biopsies, which increased detection of 
CIN2+ (118, 119). The policy of continued monitoring of women with CIN1 was 
developed from the TOMBOLA trial to reduce potential over-treatment of regressive CIN1-
2 (119). 
Treatment for CIN2+ is recommended by most guidelines in countries with organized 
screening. Women under age 40 diagnosed with CIN 1 are usually invited for follow-up 1 
year later, while treatment is recommended for women older than 40. Alternatives of 
management and treatment for CIN include ablative techniques such as cold knife cone 
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biopsy, loop electrosurgical excision procedure (LEEP), electrofulguration, laser conization, 
laser ablation, cryotherapy and hysterectomy.  There were no significant differences in 
treatment outcome according to a recent published review (120) .  
Literature reviews have shown an increased risk of cervical cancer after treatment, which 
mandates more frequent follow-up (121, 122). The incidence of cervical cancer was higher 
among treated women than among untreated women (37 vs 6 cervical cancer cases)(123). 
According to a 2014 study by Stander et al., women with CIN3 were at increased risk of 
mortality (standardized mortality ratio 2.35, 95% confidence interval 2.11 to 2.61) from 
ICC or vaginal cancer, compared with women in the general population (122) . Their study 
also showed a higher incidence of cancer among those treated with cryotherapy.  
LEEP is recommended in Sweden and is the most commonly used treatment in Swedish 
health care.  Moreover, women treated for CIN are at increased risk of adverse birth 
outcomes; cold-knife conization has been specifically associated with increased perinatal 
mortality, preterm delivery, extreme preterm delivery and low birth weight (124, 125).    
 
2.3.4 Human Papillomavirus vaccines 
Two prophylactic HPV vaccines are available for cervical cancer prevention: Gardasil
®
 
(quadrivalent vaccine targeted at HPV types 6, 11, 16 and 18) developed by Merck 
(Whitehouse Station, New Jersey, USA) and Cervarix
® 
(bivalent vaccine targeting HPV 16 
and 18), developed by GlaxoSmithKline (Brentford, Middlesex, UK), both of which target 
HPV 16 and 18,which account for around 70% of cervical cancers worldwide. Two studies, 
FUTURE I and FUTURE II, evaluated Gardasil
®
, while PARTICIA and the Costa Rica HPV 
Vaccine Trial (CVT) evaluated Cervarix
®
. The studies found that both vaccines show high 
and similar efficacy. Phase III trials are currently underway. A nine-valent vaccine targeting 
HPV 6, 11, 16, 18, 31, 33, 45, 52 and  58 was recently developed and is expected to prevent 
90% of cases of invasive cervical cancer (126). Three systematic reviews of the quadrivalent 
and bivalent HPV vaccines presented a significantly lower risk of CIN2+ in women that was 
vaccinated compared with unvaccinated women (127-129).  The vaccines have no therapeutic 
effect on established HPV infections or on CIN. However, the rate of reduction varied 
according to whether women had a history of exposure to HPV 16 or HPV 18. However, the 
vaccine would be effective in 90% of HPV naïve women. A recent study found that the HPV 
vaccine had high efficacy against CIN2+ in women with serological evidence of past 
infection with HPV type 16 or 18, but without active infection at the time of vaccination, 
suggesting that these women would also benefit from HPV vaccination (130).  Both HPV 
vaccines are associated with cross-protection against HPV types not included in the vaccine 
(HPV 31 for Gardasil and HPV 31, 33, 52, 45 and 51 for Cervarix). Studies have shown that 
Gardasil has been proven efficacious in women aged 24-45 and men aged16-26 for incident 
HPV infections, genital warts, anal intraepithelial neoplasia and for CIN (solely in women). 
However, concerns have arisen that an empty ecological niche could be developed for other 
HPV types if HPV 16 and HPV 18 are eradicated, but as yet there is no proof of this. Safety 
evaluations following the introduction of the vaccines have shown that they are very safe. 
One study compared the incidence of 53 serious events in HPV-vaccinated girls with non-
vaccinated girls in Sweden and Denmark after the introduction of the vaccine, and found no 
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evidence supporting associations between exposure to quadrivalent HPV vaccine and 
autoimmune, neurological or venous thromboembolic adverse events (131).  High coverage 
was first achieved in Australia and evaluations have shown a reduction in genital warts both 
within the vaccinated group of women and among men, suggesting herd immunity (132). 
Also, in Sweden reduction of genital warts has been demonstrated after 2 doses of vaccine 
(126).  In Sweden, HPV vaccination has been offered to girls aged 10 within the framework 
of the organized school vaccination program. Some counties in Sweden have offered catch-
up vaccination to girls age 18-26. Duration of vaccine efficacy is a key parameter. However, 
studies to confirm a reduction in the number of cervical cancer cases are still lacking. Thus 
the HPV vaccines suggest sustained immunity and could potentially change the screening 
approach.  
 
2.3.5 A summary of cost-effectiveness studies on screening for cervical 
cancer and vaccination 
 
Screening 
Cost-effectiveness studies prior to 2000 focused on evaluating available screening 
technologies such as liquid based cytology (LBC) and testing with HPV for primary 
screening alone and for follow-up of ASCUS and LSIL/CIN1 compared with conventional 
Pap smear. A switch from Pap smear to LBC in Sweden has been proposed and has been 
found to be cost-effective internationally. However, since the previously cited study found no 
statistically significant difference between LBC and Pap smear for detection of HSIL/CIN2+ 
(133) or in cost-effectiveness, comparisons should be regarded with caution. Reviews of cost-
effectiveness analysis of screening with HPV tests in addition to conventional cytology 
concluded that screening for HPV is potentially-cost-effective, provided that the time interval 
between screenings is adjusted for women above 30 or 35 years (134). HPV testing combined 
with cytology at 2-3 year intervals for women above age 30 or 35 years with ASCUS has 
proven to be less costly and may potentially increase life expectancy compared with 
conventional cytology alone (135). Annual cytology-based screening also proved to be more 
costly and led to more follow-up procedures, with little gain in life expectancy. Furthermore, 
studies suggest that HPV DNA testing followed by cytology to triage women who are HPV-
positive may be a cost-effective screening strategy for older women (136, 137) . Recent 
clinical trials confirming the  high sensitivity and specificity of HPV testing in primary 
screening using repeat HPV self-sampling at home at short intervals (112, 114) and more 
recent cost-effectiveness studies showing that clinic-based HPV testing in primary screening 
and Pap smear triage of ASCUS-LSIL (138, 139) could be effective and/or cost-effective 
indicate a role for HPV testing in the preventive program for cervical cancer in Sweden. 
However, there are too few cost-effectiveness studies on HPV self-sampling performed at 
home compared with clinic-based cytology screening. Nevertheless, one study built on data 
from a single clinical trial confirmed that HPV self-sampling may potentially be a cost-
effective option (140). Since the effectiveness of a screening program relays on participation 
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and compliance, acceptance among the population must be high towards self-sampling per 
formed by the women themselves. The aforementioned study found that over half (60%) of 
the women in the study group preferred a self-sampling performed at home as it were easier 
to perform at home and created less of an inconvenience for the women, provided it is as 
effective as clinic-based testing. Organized screening programs are both highly time 
consuming and resource intensive. In Sweden, annual direct disease-related screening costs 
are covered by the publicly funded Swedish national healthcare service.  Both attendance and 
non-attendance within the organized screening program will inevitably generate as yet 
unknown and unaccounted for future costs for society. The availability of HPV testing both 
in the clinic and at home raises the question of whether to implement HPV testing in primary 
screening for detection of high-risk patients in the general female population. However, cost-
effectiveness studies are still needed. We lack published cost-effectiveness studies on home-
screening for HPV compared with clinic-based cytology screening. Furthermore, estimates of 
disease-related direct and indirect costs are needed and should be included in economic 
evaluations according to health economic evaluation recommendations (55). 
 
Vaccination in combination with screening 
Much of the epidemiology and the natural history of infections with HPV, cervical dysplasia 
and cervical cancers are still unknown and in need of further research. Both the effectiveness 
and cost-effectiveness of HPV vaccines will depend on the organized screening program, the 
HPV vaccination strategy and the overall costs of the HPV vaccination program. Previous 
cost-effectiveness models for HPV vaccine have examined the effects of preventing HPV 
infection on the incidence and mortality rate of cervical cancer. Cohort models and dynamic 
transition models have been used to evaluate the effectiveness of HPV vaccine. A third 
category is the hybrid model, which uses a combined approach. The cohort model simulates 
the natural history of HPV and cervical cancer of a cohort over its expected life time.  Cohort 
models (health-state transmission models) are generally linear and probabilistic, while 
dynamic models are non-linear and deterministic since they track populations over time and 
take birth and death into account. Dynamic models take the rate of HPV infection into 
account. The rate of HPV infection depends on the sexual behavior of the population and the 
distribution of HPV infection. The strength of the dynamic model is that the herd immunity 
(immunity occurring when vaccination is performed on a significant proportion of a 
population, which also has an effect on those who have not developed immunity) resulting 
from the HPV vaccination program can be evaluated by methods such as exploring the effect 
of vaccinating boys, or patterns of sexual activity at onset of vaccination (141). Dynamic 
models have examined the reduction in incidence of HPV infection in relation to a vaccinated 
population. A  study assumed that 80% of women were vaccinated  before onset of sexual 
debut and projected a 92% reduction of the incidence of infection with HPV among young 
women aged 15-19 (142). 
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Limitations in dynamic models relate to the simplification of the complex and as yet highly 
undefined natural history of HPV infection, due to constraints in the modeling technique. 
This could lead to underestimations of the benefits of screening when evaluating screening 
alternatives with complex triage algorithms (142). To handle such limitations, hybrid models 
can be used. Hybrid models can project HPV incidence for various vaccination  
program scenarios and allow the outcome to be put into a cohort model to further examine the  
effects of herd immunity on reducing cervical cancer incidence and disease related  
mortality, while simultaneously taking into account the complexity of triage algorithms. 
 
 
Cost-effectiveness of screening and vaccination 
Taking into account various settings, with and without screening, for use in various model 
structures such as cohort, dynamic or hybrid models, the reviews of such cost-effectiveness 
models suggest that HPV vaccine programs could potentially reduce the incidence of CIN, 
cervical cancer and mortality (143-145). Suggestions are therefore based on models that 
project outcomes with assumptions concerning the lifelong duration of vaccine efficacy and 
high coverage. Such assumptions may need to be modified to simulate more real-life settings 
with lower coverage (144). Therefore, model-projected results must be updated as vaccine 
programs are implemented in different settings and as evidence concerning duration and 
coverage accumulates. In the aforementioned reviews, vaccine dose price affects the cost-
effectiveness of adding vaccination to the screening program. In countries with no organized 
screening, potentially HPV vaccination could be a cost-effective prevention method 
compared with no prevention (146). Also, as can be expected based on vaccination trials, 
solely administering HPV vaccinations to young girls prior to sexual debut could potentially 
be a cost-effective option compared with HPV vaccination for girls, boys and catch-up 
vaccinations. However, vaccinating boys also provides a direct benefit by reducing HPV-
related cancers and protecting against genital warts in men. The indirect benefits of increased 
herd immunity include protection of unvaccinated men and women in general, as well as men 
who have sex with men. HPV-related diseases are less common among men than in females 
and men benefit from vaccinated women through herd immunity. If coverage is less than 
50% including men in the HPV vaccination program is potentially cost-effective (132). The 
question of whether to include men in the vaccination program is ongoing. In Australia, the 
government approved vaccination of men in 2012 and commenced in 2013. One model study 
of a heterosexual population projected near elimination of genital warts in both men and 
women (147).  However, as more empirical data on herd immunity, vaccine coverage and 
vaccine duration become available, models will need to be updated.  
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Screening in the era of HPV vaccines 
A recent review concluded that existing cervical cancer screening techniques are effective, 
although organized screening programs should consider implementing HPV testing and 
further process developments for alternative screening methods (148). The question of 
whether and how screening methods should change when combined with HPV vaccine 
programs is complex and depends on a number of key issues, some of which are still 
unknown. Such key issues include performance of HPV testing, reduction in the rate of CIN 
and cervical cancer, and whether HPV vaccination will alter participation and compliance 
with the screening protocol. One potential future approach for vaccinated women is HPV 
testing in primary screening with cytology triage, while postponing onset of screening to a 
later age and employing less frequent screening intervals over the lifetime of these women 
(137). Given the potential for cervical cancer to become a low-incidence disease in the future, 
the current screening policy needs to be reconsidered.   
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2.4 BARRIERS TO AND FACILIATORS OF COMPLIANCE WITH CERVICAL 
CANCER SCREENING 
 
For a cervical cancer screening program to be effective, screening procedures must be 
acceptable to the population (the sixth criteria for implementing a screening program 
according to the WHO) and the screening schedule must be closely followed. Compliance 
with current screening policy using conventional cytology and factors that affect compliance 
have been widely evaluated in the past. However, a change from conventional cytology 
screening to HPV testing in primary screening, based on previous evidence, suggests that 
time intervals between screenings could be longer and triage testing for HPV-positive women 
should be implemented. The implementation of HPV testing could potentially alter public 
perception of cervical cancer by clarifying the etiologic role of a sexually transmitted virus. 
This may affect coverage or participation, as well as compliance with screening protocols. 
Such a change could possibly have a different effect on women of lower socioeconomic 
status, which needs to be addressed. A literature review was therefore conducted on PubMed 
to identify relevant publications containing information on knowledge of and attitudes toward 
HPV, HPV screening, screening attendance and socioeconomic status, coverage, as well as 
participation and compliance. This chapter summarizes the relevant findings from these 
studies.  
 
2.4.1 Knowledge of HPV and related diseases 
 
Overall, women with lower socioeconomic status are less knowledgeable about HPV, its 
relationship to cervical cancer and its risks. Interesting studies performed just before the 
vaccines were released examined awareness and knowledge of HPV as well as barriers to 
cervical cancer screening. One international study investigated the level of knowledge and 
barriers to cervical cancer screening among female university students in Malaysia and 
concluded that important correlates of knowledge of cervical cancer were age, marital status, 
ethnicity, family income level and university faculty attitudes (p=0.003; p=0.001; p=0.002; 
p=0.002; p=0.001 and p=0.002; respectively) (149). In this study, the most commonly known 
and reported risk factor for cervical cancer was having more than one sex partner (77.5%), 
while the least commonly known risk factor concerned the relationship between HPV and 
cervical cancer (51.2%). In a UK study, face-to-face interviews were conducted and 
participants were asked about risk factors for cervical cancer; women and generally better  
educated people had more knowledge (150).  An association with social class (p<0.001) was 
found in Germany (151). In that study, age at first screening was associated with social class 
(p<0.001). Approximately 70% of the women considered themselves insufficiently informed 
about risk factors and only 3% knew that infection with HPV is a risk factor for cervical 
cancer. Another study assessed the proportion of women who had heard of human 
papillomavirus (HPV) in four Nordic countries (Denmark, Iceland, Norway, and Sweden) 
and examined correlates of this awareness (152). In this study, 60% of all participants had 
never heard of HPV. Correlates associated with having heard of HPV in the past included a 
history of genital warts (odds ratios, OR=2.57; 99% confidence intervals, CI: 2.38-2.76) and 
educational level (OR=2.06; 99% CI: 1.92-2.21). Another study, carried out in Sweden just 
before HPV vaccination was included in the Swedish national vaccination program, 
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concluded that overall knowledge of HPV among parents and young adults was modest, 
with a significant proportion of respondents not knowing or being uncertain about whether 
HPV can cause genital warts, cervical cancer and other cancers (153). Since most studies 
were carried out before the release of the HPV vaccine or introduction of the HPV 
vaccination program (2007-2010), general knowledge and awareness among populations 
may have increased. However, two European studies conducted in France and Germany 
concluded that knowledge about HPV and its relationship to cervical cancer was 
inadequate, and that there was a low prevalence of such awareness among young women 
(154, 155). In the study performed in France, only 14% mentioned HPV infection as the 
cause of cervical cancer, even though 76 % were aware of the HPV vaccine. Important 
correlates for acceptability of the HPV vaccine included knowledge about the vaccine and 
acceptance of other vaccines. In Germany, participants included female university students 
age 19-35 and a lower score on HPV knowledge (<median = 12, ranged 1-17) could be 
predicted among women in social sciences/humanities programs (OR = 3.68, 95% CI 1.99-
6.79) and non-participants in cervical cancer screening (OR = 2.04, 95% CI 1.02-4.07). 
 
 
2.4.2 Coverage and participation 
Introducing HPV testing in primary screening will allow longer time intervals due to the 
test’s high performance in detecting CIN2+. Health professionals are engaged in ongoing 
debate and speculation as to whether such testing will effect a change in behavior among 
women eligible for clinic-based screening. However, the literature contains no published 
evidence to this effect.  Several countries practice either opportunistic screening or screening 
within the framework of an organized screening program, or a combination thereof to 
increase participation. In many countries, women must pay (net cash outlay) for spontaneous 
screening; since HPV testing is currently much more expensive than conventional cytology 
with Pap smear, screening inequalities could possibly arise between women in different 
socioeconomic classes. Hypothetically, women in higher socioeconomic classes would be 
more likely to choose HPV testing, while women in lower socioeconomic classes would 
choose a Pap smear. Two studies address this problem (156, 157). If Pap smear is not offered 
as an alternative, the high cost could deter women in lower socioeconomic classes from 
participation in screening.  However, use of HPV self-sampling at a lower cost than clinic-
based screening could increase participation among women in lower socioeconomic classes.  
A small study of non-responders to the first invitation to clinic-based screening was 
conducted in Italy to investigate the feasibility of HPV self-sampling. Researchers concluded 
that there is acceptance for HPV self-sampling and that mailing a device for HPV DNA self-
collection to non-responders as an alternative to conventional cervical cancer screening 
might increase compliance among the population, compared with repeated invitation to 
clinic-based cytology (158). The study reported a 5% increase in coverage, which is 
considered to be relevant in terms of public health (2% when only considering under-covered 
women whose last Pap smear was more than 5 years earlier). The 2005 Danish Health 
Technology Assessment of Cervical Cancer from Sundhedsstyrelsen et al. (159) found that 
a 1% absolute increase in the coverage rate achieves a similar or equal reduction of risk as 
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does reducing the screening interval from 3 to 2 years, an outcome with an estimated 
annual gain of 85 life-years in Denmark.  
 
The future increase in population coverage or participation cannot be predicted based on 
existing literature. However, HPV self-sampling devices could potentially increase 
participation: higher performance in detection of CIN2+ and a reduced risk for developing 
cervical cancer following a negative HPV test will increase the safety of women who are 
not regular participants in the screening program. Consequently, this approach could reduce 
the incidence of cervical cancer and differences between socioeconomic groups.  However, 
data are lacking on the possible increase in adverse outcomes, including unnecessary 
referrals for diagnostic follow-up and over-diagnosis, with subsequent overtreatment of 
lesions that may otherwise spontaneously regress. In the future, more research on adverse 
events is needed as HPV-based screening protocols replace the existing practice of 
conventional cytology-based cervical cancer screening. 
 
2.4.3 Feasibility of HPV self-sampling  
Previous studies have assessed the value of HPV-self sampling as a complement to 
conventional cytology. Specifically, the studies explored whether use of HPV self-sampling 
devices could increase screening coverage and participation among women who are 
nonparticipants or who do not participate regularly. Currently under debate is the use of HPV 
self-sampling as a follow-up method for secondary screening of women found to be HPV-
positive and cytology-negative in primary screening. Successful HPV self-sampling requires 
a high level of acceptance among the population. Studies exploring acceptance of HPV self-
sampling showed that apart from marital status, ethnicity and age, the most important 
correlate was high educational level (160-165). However, a Swedish study of women who 
had not attended the organized cervical cancer screening program for over 6 years found no 
significant difference in use of self-sampling based on age, country of birth, occupation or 
marital status. Attitudes toward HPV self-sampling differed among responders and non-
responders. Women who performed HPV self-sampling were more positive toward self-
sampling (p<0.01)(166). Thus, acceptance was also found among non-responders (women 
who do not respond to screening invitations) (165, 167-169). Direct home mailing of the 
HPV self-sampling test was the preferred method to reach women (167, 170-172). One study 
with a large population sample examined HPV self-sampling as a method for primary 
screening and found that the participation rate was lower for the entire sample population 
compared with conventional cytology. However, when excluding women whose disease was 
detected through self-sampling and women who did not receive the HPV self-sampling kit by 
mail, the participation rate was almost 100% (173). Consequently, HPV self-sampling could 
possibly provide greater access to screening if the supporting administrative organization has 
accurate addresses for all women.    
In conclusion, women of low socioeconomic status will be less likely to accept HPV self-
sampling. However, HPV self-sampling may increase compliance across all socioeconomic 
groups. HPV self-sampling could also reduce overall costs for the organized screening 
program because of its low direct medical cost and because women can perform the test 
during their leisure time, avoiding loss of productivity and the other necessary direct non-
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medical costs associated with time and travel incurred for clinic-based screening. Moreover, 
in countries where women pay for screening tests themselves there would be lower direct 
medical costs and fewer costs incurred by the women compared with clinic-based screening. 
Use of healthcare services in general, especially preventive health programs, is inversely 
related to the price the individual pays or the costs incurred. High prices and costs tend to 
deter use, while lower prices and costs encourage use of healthcare services (174). 
Consequently, HPV self-sampling could lead to higher participation or compliance among 
women who perceive costs associated with clinic-based screening to be high and who are 
therefore deterred from attending clinic-based screening.  
 
2.4.4 Compliance with less frequent screening 
 
Primary screening 
Compared with the current 3-year screening interval for cytology-based testing, a 5-year 
interval is recommended with HPV testing following a negative test. To date, there are no 
studies to confirm compliance with the recommended 5-year screening interval in HPV 
testing. However, in Sweden a 5-year interval is used with conventional cytology for women 
aged 50-60, showing an overall high rate of compliance (84% within 5.5 years) (85). Shorter 
intervals are common in other countries that practice a combination of opportunistic 
screening and organized screening programs. A US study found that among all participants, 
81% expected to have a Pap test within the year, while 91% of women whose most recent 
Pap test was within the past year expected to be screened again within 1 year (175). Another 
study found that 50% of women accept a 3-year Pap test interval, as do a 32% minority of 
physicians, while the majority of primary care physicians continue to recommend shorter 
intervals (176). This study showed an association between shorter screening intervals and 
higher socioeconomic levels. Should the problem of over-screening increase among women 
in higher socioeconomic levels, it is unlikely to be accompanied by an increase among 
women in lower socioeconomic levels. Among frequently screened women, a 5-year interval 
may seem too long and lead to increased use of spontaneous or opportunistic screening.  
 
Secondary screening 
The recommended follow-up period for repeat screening after an HPV-positive and cytology-
negative test is from 6 months to 1 year. As implied by previous studies, socioeconomic 
status may influence compliance with the follow-up screening protocol. In one study of HPV-
positive women with normal cytology who repeated the HPV test 1 year later, results show 
that immediate colposcopy is preferable to repeat HPV testing for monitoring of HPV 
infections (177). The preference for that alternative was associated with the desire for quick 
resolution and concerns about disease progression to cancer. Decreased compliance with 
follow-up may be related to the initial sampling technique depending on whether the initial 
sampling technique provides for reflex cytology (liquid based cytology) requiring no 
additional clinic visit, or whether further testing for cytology sampling requires women to 
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return to the clinic. In addition, problems may arise when an HPV-positive woman 
subsequently tests negative on cytology and is asked to return for further testing 1 year later 
in order to avoid unnecessary colposcopies and biopsies, as well as unnecessary treatments 
associated with further risk of adverse events. By using liquid-based cytology with co-
sampling, HPV-positive women who are cytology-negative only need to  return for follow up 
with a new HPV test 1 year later, thereby eliminating the need for an extra medical visit. One 
trial showed that compliance with repeat testing was slightly higher than trial baseline 
compared with subsequent rounds with colposcopy, showing a slight loss at follow-up (178). 
One study confirmed that personal counseling by phone increased compliance 1 year after an 
initial positive HPV test (179). Effective communication tools need to be developed to ensure 
compliance among HPV-positive women with negative cytology and should be made 
available to both women eligible for screening and physicians.  Use of interventions to 
provide information help women make an informed decision and could potentially reduce 
over-screening (180, 181). Another strategy might be to discontinue insurance coverage for 
annual cytology tests when no indication is present. Additional approaches aimed at medical 
practices and at national health preventive program planning, include updating cervical 
cancer screening quality of care measures (i.e. screening history with test results) within 
national registries, which could then be used to evaluate performance and lead to more 
consistent recommendations concerning both spontaneous and opportunistic screening alone 
or in combination with organized screening. 
 
2.4.5 HPV-positive results and how it affects woman 
Several studies and reviews have addressed the anxiety experienced by women after a 
positive cytology test result (182, 183). Anxiety relates to disease progression, sexual 
function, body perception and future infertility. There are indications that that anxiety 
correlates with socioeconomic status. One study investigating the impact of abnormal Pap 
smear results on health-related quality of life (HRQL) showed that 35% of women from  
lower socioeconomic groups displayed clinically significant anxiety at 12 weeks, did not 
completely understand the information concerning their results and perceived themselves to 
be at higher risk of cancer (184). These findings imply that anxiety is associated with lack of 
knowledge about the disease and educational level. Such studies are also relevant for HPV-
based screening where they may have even greater importance, since even higher proportions 
of women are HPV-positive (185). Also, concern over HPV as a sexually transmitted 
infection (STD) may affect sexual behavior and relationships (186). This may be especially 
relevant among less educated women who have difficulty understanding the relationship to 
cancer (187). Concern exists over how to effectively communicate a positive test result and 
general information about HPV (188, 189). In this regard, an Australian study showed that 
personal counseling is the preferred way to communicate tests results in order to reduce 
anxiety (190).  
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2.4.6 Combined screening and vaccination 
There are concerns about preventive vaccination and screening in current and future 
generations. Some speculate that vaccinated women will defer screening as a result of altered 
attitudes toward screening (191-196). However, current knowledge of HPV suggests that the 
women at greatest risk are those who choose not to be vaccinated and those who do not 
participate in screening. One study that models screening outcomes was externally 
consistent with results from multiple and independent sources. Expected reductions in 
lifetime risk of cancer due to screening every year or every other year were 76% and 69%, 
respectively. The reduction from vaccination alone was 75%, although parameter 
uncertainty concerning the natural history of type-specific HPV infection is present (197). 
Screening participation and/or HPV vaccination is immensely important, but concern has 
been expressed that vaccinated women may alter the screening habits. Previous research has 
looked at whether prior experience of disease and screening participation by a woman’s 
mother could affect women’s future screening habits; the results are inconclusive (193-196, 
198). One study of a representative sample in the British population (198) showed that 
screening attendance correlated with level of education (odds ratio [OR] = 1.66, confidence 
interval [95% CI]: 1.07-2.56) and marital status (OR = 2.04, 95% CI: 1.37-3.03). Acceptance 
of screening with HPV testing could be predicted by regular attendance for cervical cancer 
screening (OR = 1.58, 95% CI: 1.03-2.42) and by an ethnic white background (OR = 2.20, 
95% CI: 1.18-4.13). The age of the daughter was the sole predictor of acceptance of HPV 
vaccination, while the mothers most likely to accept vaccination were those with daughters 
aged 13-16 (OR = 2.91, 95% CI: 1.27-6.65).  A different study (193) showed that vaccinated 
women had a more positive attitude toward practicing safe sexual behavior, but less than 5% 
correctly identified cervical cancer screening guidelines. The findings from this study do not 
support previous research that the HPV vaccination program could have a negative impact on 
screening and sexual behavior. Another study examined the association between screening 
participation by mothers and vaccination of their daughters, and used a model simulation to 
estimate the effects of this on cancer incidence (195). The results showed that HPV 
vaccination status was significantly associated with screening participation by mothers (odds 
ratio: 1.54 [95% confidence interval: 1.51-1.57]). Only 13% of girls refuse to participate in 
either program, compared with 23% when screening alone is available and participation by 
the mother in screening was used as a proxy to determine the girls’ future screening habits as 
adults. However, this model simulation only resulted in slightly lower estimates for the 
impact of vaccination on incidence of cancer, compared with estimates assuming no 
association. Empirical data concerning the above has yet to be published.  
HPV vaccination is a preventive strategy for cervical cancer. However, cervical cancer 
screening must continue since the vaccines will not protect against the HPV types that are not 
included in the first generation vaccines. HPV testing as primary screening is still relevant for 
vaccinated women (199). Further research on vaccinated women and screening algorithms 
will help define future preventive policies for cervical cancer and possibly for other HPV-
related cancers as well.    
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3 AIMS OF THE THESIS 
3.1 GENERAL AIMS 
The aims of the thesis were to study  the efficiency in the allocation of resources to cervical 
cancer screening  of importance for setting priorities: the cost of the most prevalent HPV 
related diseases namely cervical dysplasia, cervical cancer and genital warts,  modeling the 
cost-effectiveness of cervical cancer screening and exploring knowledge of HPV, compliance 
with screening and its correlates.  
3.2 SPECIFIC AIMS 
The specific aims of the thesis were as follows: 
3.2.1 Paper I 
To evaluate the cost-effectiveness of human papillomavirus testing (HPV triage) for follow-
up and management of women with index smear diagnosis of ASCUS and LSIL within the 
framework of the Swedish organized screening program. 
3.2.2 Paper II 
From a societal perspective, to evaluate the cost-effectiveness of HR-HPV testing using self-
collected vaginal samples within the framework of the Swedish organized screening program.  
3.2.3 Paper III 
This study aims to identify possible barriers to and facilitators of cervical cancer screening by 
(a) estimating time and travel costs and other direct non-medical costs incurred by women 
attending the clinic-based cervical cancer screening program, (b) investigating screening 
compliance and reasons for noncompliance, (c) determining women’s knowledge of human 
papillomavirus (HPV), its relationship to cervical cancer, and HPV and cervical cancer 
prevention, and (d) investigating correlates of HPV knowledge and screening compliance. 
3.2.4 Paper IV 
The present study is aimed at estimating costs for prevention, management and treatment 
associated with cervical dysplasia, cervical cancer and genital warts from a societal 
perspective in Sweden in 2009, 1 year before implementation of quadrivalent HPV 
vaccination program. 
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4 MATERIALS AND METHODS 
4.1 MODELING COST-EFFECTIVENESS OF HPV TRIAGE FOR FOLLOW UP 
OF WOMEN WITH MINOR CYTOLOGICAL ABNORMALITIES (PAPER I)  
 
4.1.1 Modeling approach 
We created a decision tree-based model to evaluate the cost-effectiveness of three follow-up 
strategies from a health care perspective:  
 
Follow-up strategies for women with index smear diagnosis of ASCUS and LSIL detected in 
the organized screening program at local outpatient clinics: 
A) Cytology includes a visit to a gynecologist for a repeat Pap smear. When cytology 
result shows cytological abnormality, with ASCUS as the cut-off, the women are 
referred for a third follow-up visit to a gynecologist for colposcopy with biopsy. If 
the follow-up with Pap smear is within normal limits, the woman is referred back to 
the organised screening program for a new Pap smear 3 or 5 years later (depending 
on age). 
 
B) HPV triage includes a follow-up visit to a midwife for HPV testing with HC2 
(Hybrid Capture 2®, Digene Corporation, Gaithersburg, Maryland, USA). All HR-
HPV-positive women are referred for a third follow-up visit to a gynecologist for 
colposcopy with biopsy. All HR-HPV-negative women with index smear 
diagnosisof ASCUS or LSIL are referred back to the organised screening program 
for a new Pap smear 3 or 5 years later (depending on age). 
 
C) Immediate colposcopy with biopsy includes a visit to a gynecologist for 
examination including colposcopy and directed biopsies. If there is no 
colposcopically visible lesion a biopsy is taken. This follow up strategy were 
assumed to have the highest sensitivity and specificity 100% (i.e., the gold 
standard), and constitutes the reference examination for diagnosing CIN. 
 
The time frame for the study was one year from index smear diagnosis of ASCUS and 
LSIL in the organized screening program.  
 
4.1.2 Population and setting 
Data on test accuracy which populated the model were data from one clinical trial 
performed within the Swedish organized screening program (200). The women had 
undergone screening with Pap smear taken by a midwife at a local outpatient clinic 
according to current policy and practice. The study group within the clinical trial consisted 
of 177 women aged 23 to 60 years with a diagnosis of ASCUS or LSIL on the index smear. 
They were all were referred for gynecological examination because of the aforementioned 
screening results. The mean age of the women was 34 years. The group consisted of 177 
women and was subdivided according to age and ASUS or LISL on index smear; women of 
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all ages (23–60 years), women up to age 30 and women aged 30 years and older with 
diagnose ASCUS/LISL considered as one group and ASCUS and LSIL as two separate 
groups. 
 
4.1.3 Health economic data 
 
The effect data was based on prevalence of HR HPV, prevalence of CIN2+ and the different 
screening test performance (i.e. sensitivity and specificity). Screening tests included in the 
follow-up strategies were repeat conventional cytology with Pap smear, HPV testing with 
HC2 (Hybrid Capture 2) and colposcopy with biopsy (i.e. the gold standard).  
 
Table I.1 Prevalence of HR HPV, CIN2+ and performance of follow-up strategies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“a)Colposcopy with biopsy is referred to as gold standard” 
 
 
Parameter a) All women  Women <30 years Women  
>30 years 
ASCUS/LSIL 
     Prevalence, CIN2+ 
     Prevalence,  HR-HPV 
 
Sensitivity for CIN2+ 
     Cytology 
     HPV triage 
 
Specificity for  CIN2+ 
     Cytology 
     HPV triage 
 
ASCUS 
     Prevalence, CIN2+ 
     Prevalence, HR-HPV 
 
Sensitivity for CIN2+ 
     Cytology 
     HPV triage 
 
Specificity for CIN2+ 
     Cytology 
     HPV triage 
 
LSIL  
     Prevalence, CIN2+ 
     Prevalence, HR-HPV 
 
Sensitivity for CIN2+ 
     Cytology 
     HPV triage 
 
Specificity for CIN2+ 
     Cytology 
    HPV triage 
 
 
 
0.21 
0.66 
 
 
0.61 
0.82 
 
 
0.56 
0.39 
 
 
0.19 
0.44 
 
 
0.60  
0.60 
 
 
0.69 
0.60 
 
 
0.22 
0.74 
 
 
0.61 
0.89 
 
 
0.51 
0.30 
 
 
 
0.23 
0.81  
 
 
0.50  
0.89 
 
 
0.52 
0.22  
 
 
0.17 
0.67 
 
 
0.67 
0.67 
 
 
0.60 
0.33 
 
 
0.25  
0.85 
 
 
0.47  
0.93  
 
 
0.49  
0.18 
 
0.20 
0.54   
 
 
0.70  
0.75 
 
0.59 
0.52 
 
 
0.21 
0.32 
 
 
0.57 
0.57 
 
 
0.74 
0.74 
 
 
0.20  
0.65 
 
 
0.77  
0.85  
 
 
0.52  
0.40 
  49 
The cost data included average unit costs for the different quantities obtained from local and 
nationwide sources in Sweden. All costs were based on “Patient-level Clinical Costing” 
(known as cost per patient (KPP) in Sweden). All costs in the study were expressed in 2008 
Swedish Kronor (SEK).Costs were not discounted due to the short time frame of only one 
year. 
 
4.1.4 Sensitivity analysis 
 
A one way sensitivity analysis was conducted varying the model parameters to examine 
when HPV triage becomes a cost-effective alternative. Due to the uncertainty in the data on 
sensitivity and specificity from the clinical trial data,  data on the accuracy of HPV triage 
for detection of CIN2+ were complemented with accuracy presented in published meta-
analyses (201-204). 
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4.2 MODELING COST-EFFECTIVENESS OF HPV SELF-SAMPLING IN 
PRIMARY SCREENING (PAPER II) 
4.2.1 Modeling approach  
A Markov simulation model was developed to simulate the natural history of HPV, cervical 
dysplasia and cervical cancer. The model included following health states: healthy (i.e. no 
ongoing HPV infection), ongoing HPV infection, CIN1, CIN2+ and cervical cancer 
subdivided into the FIGO stages I, II, II and IV. In the model, women started out as healthy at 
age 15. Health states then altered according to a set of probabilities that occurred within 
predetermined yearly cycles until the women reached age of 85 years or died from either 
cervical cancer or other causes. The women was every yearly cycle at risk of attaining an 
infection with HPV via sexual transmissions, which with time could progress to CIN1 or 
CIN2+, continue being in a persisting state or clear. CIN1 or CIN2+ lesions could either 
regress to a healthy status, continue being in same state or progress their disease to invasive 
cervical cancer. The women that progressed from cervical dysplasia to invasive cervical 
cancer could progress from a FIGO stage I to a more advanced FIGO stage (II–IV).Women 
with FIGO stage I–IV could be diagnosed through screening or by presenting with 
symptoms. Simplifications of the model were necessary; women with an ongoing HPV 
infection, CIN1 and CIN2+ could only have their infection of lesions detected during 
screening; cervical cancer survivors could only die from causes other than cervical cancer. 
  
Screening strategies with alternative frequencies with 2, 3, 3/5 and 5 years’ time interval 
between the screening opportunities: 
A) A combination strategy including conventional cytology with Pap smear from the 
age of 23 untill age 34 and  HPV self-sampling performed by the women themselves 
in the privacy of their home from age of 35 until 60 years.  The women were assumed 
to be using a “Viba-brush (Rovers Medical Devices, B.V., Oss, the Netherlands)” for 
the procedure of collecting cells which they afterwords applied on to an indicating 
“FTATM Elute Micro Card (GE Healthcare, Chalfont St Giles, UK)” , and therafter 
mailed in for HPV analysis with “RT-PCR,  detecting HR-HPV types 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58 and 59” as previously described in detail (114-116). 
 
B) Conventional cytology with Pap smear between age 23 and 60 years.  
 
C) Status quo means screening with conventional cytology with Pap smear between age 
23 and 60 years at 3-year/5-year intervals according to current screening policy on 
age and time intervals of today. 
 
D) No screening offered to the women population which was used as reference strategy 
for the model validation.   
Follow up and screening protocols were set according to Swedish for  screening and practice 
(see Figure II:1.)  
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Figure II:1. Screening, management and follow up applied in the model structure.  
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4.2.2 Population and setting 
 
The model was populated with an assumed Swedish female cohort of all women aged 15 to 
85 years. Women were eligible for screening between age 23 and 60. All different screening 
strategies and follow-up were assumed to be under control of the organized cervical cancer 
screening program.   
 
4.2.3 Validation of the model 
 
For validation of the model we used “no screening” as our reference strategy. We computed 
the model by changing the age-specific incidence rate of HPV infection within a relevant 
range to extrapolate the average annual cervical cancer incidence rates from the time before 
screening was initiated in Sweden. Conventional cytology was then added to reflect current 
screening policy and practice, population coverage and screening test accuracy. The internal 
validity of the model was then tested by comparing the model projected outcomes on cervical 
cancer incidence rate with the conventional cytology screening strategy based on empirical 
data following the implementation of organized cervical cancer screening in Sweden (1961–
2009) with the “no screening” alternative. According to this comparison of strategies, 
outcome results of cervical cancer cases closely resembled the empirical data, with a similar 
peak age group. 
 
4.2.4 Health economic data 
Data for the model was; age-specific incidence of HPV infection, transition probabilities 
between the predetermined health states; survival rates for cervical cancer after treatment and 
mortality rates derived from previously published literature and chosen by clinical experts for 
inclusion (13, 14, 26, 205-212) (see Table II:1). The relative mortality risk from other causes 
was obtained from Swedish official statistics (available in English at http://www.scb.se) 
while the age-specific incidence and mortality rates for cervical cancer in Sweden were 
collected from IARC (213-216). Data on test accuracy in the base case analyses were taken 
from previously published data (114-116). 
Cost data were incorporated into the model using a societal perspective. We therefore 
included both direct medical costs and indirect costs.  The productivity loss due to cervical 
cancer screening, diagnosis, management and treatment was based on an average monthly 
gross wage rate. All costs were expressed in 2011 Euro (€). Direct costs were mainly based 
on “Patient-Level Clinical Costing”, (KPP in Swedish), as previously described in Paper I 
and supplemented with the direct medical costs for the HPV sampling kit and virus typing at 
Uppsala University Hospital. Costs for diagnosis of cervical cancer, the procedure for staging 
and treatment of invasive cervical cancer by FIGO stage were obtained from records at 
Radiumhemmet, Karolinska University Hospital. All future costs were discounted to present 
value at 3% annually. According to published recommendations, we also included the cost of 
added life-years in the model (56, 217).  
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Table II.1. Model parameters 
Model parameter Base-case analysis 
Natural history  
Well to HPV*  0.01-0.22 
HPV to Well by age (y); 15-29/30-65/>66 0.9/1y/0.4/1y/0.2/1y 
HPV to CIN1 0.2/3 y 
HPV to CIN2+ 0.05 
CIN1 to Well 0.9 
CIN1 to CIN2+ by age (y); 15-34/>35 0.1/6 y/0.35/6 y 
CIN2+ to CIN1 0.35/6 y 
CIN2+ to Well 0.5 
CIN2+ to FIGO I 0.4/10 y 
FIGO I to FIGO II/annual probability of symptoms/5-y SR 0.9/4 y/0.15/0.84 
FIGO II to FIGO III/annual probability of symptoms/5-y SR 0.9/3 y/0.225/0.66 
FIGO III to FIGO IV/annual probability of symptoms/5-y SR 0.9/2 y/0.6/0.38 
FIGO IV annual probability of symptoms/5-y SR 0.9/0.11 
HR HPV strategy; Sensitivity for CIN1+/Specificity for CIN1+
 
 1.0/0.98 
Conventional cytology; Sensitivity for CIN1+ /Specificity for CIN1+
 
 0.75/0.72 
Coverage  0.80 
Follow up of HPV-positive or any abnormality 1.0 
Follow up of treatment of CIN or invasive cancer 1.0 
“*In the model, we do not distinguish between different HPV types. Incidence, progression and 
regression represent an average value for all HPV types.”  
 
 
4.2.5 Sensitivity analysis 
 
Due to the uncertainty in the model parameters, costs and effects were altered in the 
sensitivity analysis to investigate the impact on cost-effectiveness results. In additional 
analysis, quality of life weights were included for each FIGO state in the model for the 
duration of time spent in that state. 
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4.3 INVESTIGATING BARRIERS AND FACILITATORS TO COMPLIANCE IN 
CERVICAL CANCER SCREENING (PAPER III) 
 
4.3.1 Study design, population and data collection 
This descriptive population-based study included 1 510 women aged 23-60 attending the 
organized screening program at five different local outpatient clinics in Stockholm, Sweden. 
Self-administered questionnaires were handed out and completed by women in the waiting 
room at the outpatient clinics. Data were collected from March 2013 to April 2014. The study 
was approved by the Ethical Review Board at Karolinska Institutet, Stockholm, Sweden. 
Questionnaire 
To investigate barriers to and facilitators of compliance with clinic-based cervical cancer 
screening we constructed a questionnaire based on the recommendations of a working group 
on patient-reported costs (218), and influenced by previous described questionnaires used in 
studies on knowledge and attitudes toward HPV(152, 153, 219). The questionnaire was 
refined through a validation process.  
The first part of the questionnaire explored sociodemographic characteristics (age, marital 
and employment status, income and educational level). The second part of the questionnaire 
investigated time and travel costs and other direct non-medical costs, including mode(s) of 
transport to and from the clinic, time spent traveling, estimated distances, estimated net cash 
outlay for mode(s) of transport, ticket fares, parking fees, child care expenses, and activities 
before attending screening. This part also contained questions about estimated time taken off 
from work to attend screening; if the woman was accompanied, the companion’s relationship 
to the woman; income level and estimated time off work were also considered. 
   
We also measured the average waiting and procedure time at two outpatient clinics on 4 
separate occasions. Time was measured with a stop watch from time of arrival until departure 
the clinic. The third part of the questionnaire explored knowledge about the purpose of 
screening, if the women were satisfied with the invitation letter, compliance (screening 
attendance within one year from initial invitation) and reasons for noncompliance, knowledge 
about HPV, cervical cancer screening and the relationship to cervical cancer, as well as 
prevention methods such as screening and vaccination.  
 
4.3.2 Statistical analysis 
Prior to study start, we conducted a power calculation for sample size and determined that a 
study sample of 1500 responders would ensure a power of 0.976 to detect a difference in the 
proportion of women from different age groups concerning HPV knowledge. Data were 
entered into the Statistical Package for Social Science (SPSS software version 21.). 
Descriptive statistics including frequency distribution of variables and mean scores were 
obtained. To test internal data reliability, Cronbach’s alpha coefficient was measured and an 
alpha ≥0.70 was considered to be satisfactory. Mean differences for travel mode costs, and 
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distances were analyzed by one-way analysis of variance at the 5% significance level, with a 
Bonferroni correction. The Z-test was used to identify if sociodemographic characteristics 
differed significantly on some single (categorical) characteristic in the respondents compared 
to the whole female population. Also, we investigated if knowledge of HPV between age 
groups differed significantly by using the Z test.  
A binomial logistic regression model was used to investigate correlates of HPV knowledge 
and compliance with screening. For questions, we assigned a value of 1 to a Yes response 
(i.e. correct) and a value of 0 to No and Don’t know responses (i.e. incorrect responses). 
Correlates of knowledge were determined using a dichotomous dependent variable based on 
the median (i.e.,>5 or <5) HPV knowledge score. We performed a manual backwards 
stepwise procedure to determine the remaining variables in the model. Non-significant 
variables were excluded from the model. Variables were retained if their removal altered the 
width of the confidence intervals (CIs) of the other remaining variables by more than 10%. 
Qualitative data obtained from individual answers were used to support the quantitative data.       
 
 
 
4.4 ESTIMATE COST OF PREVENTING AND MANAGING HPV-RELATED 
DISEASES BEFORE THE INTRODUCTION OF QUADRIVALENT HUMAN 
PAPILLOMAVIRUS VACCINATION (PAPER IV) 
 
4.4.1 Study design, population and data 
A cost-of-illness study approach was applied (63) to estimate the total cost of prevention, 
management and treatment of cervical cancer and genital warts in Sweden from a societal 
perspective. We investigated costs incurred over a given one-year (2009) time period, 
regardless of date of onset. Data were collected from the target study population and cost 
estimates were extrapolated to be representative of the entire population using national 
prevalence estimates. Cost categories included: costs for medical procedures and 
management, inpatient and outpatient care, tests and drugs, as well as costs resulting from 
productivity loss (sick leave, absence from work). Swedish data on costs and prevalence of 
cervical cancer and genital warts were collected from the following sources: KPP  
(Swedish cost per patient database), Statistics Sweden (SCB), Eurostat database and the  
Dental and Pharmaceutical Benefits Agency (available in English at http://www.tlv.se),  
as well as published epidemiological and cost data. Where no data were available, best 
possible estimates or extrapolated data were used in the study. Register data on genital warts  
are lacking, since they are not included in Sweden’s mandatory surveillance of  
infectious diseases. Therefore, epidemiological data from a recent study based on  
prescription drug registers and patient registers (220) and published data from the 
United Kingdom were used to estimate rates of genital warts (221). 
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4.4.2 Investigating procedure and management of genital warts 
Regarding genital warts, to estimate treatment patterns, average number of visits, and time 
spent for each type of procedure, we developed a standardized questionnaire and sent it to 10 
physicians with extensive clinical experience in managing and treating patients with genital 
warts. The clinical expert panel included physicians from various specialties (general 
medicine, dermatology/venereology, gynecology/obstetrics) from both the outpatient and 
inpatient settings. Following completion of questionnaires, physicians in the expert panel 
were interviewed to review responses as necessary. The responses were pooled, and means, 
medians and ranges were calculated. Treatment patterns were constructed from the mean 
values and then used to determine costs. Estimates of travel time to and from care facilities 
and waiting time were taken from our previous study (travel to the clinic for screening: 44 
min; waiting time: 10 min) (paper III).  
 
4.4.3 Validity 
Cost analysis results were tested for internal and external validity as follows: sensitivity 
analysis was used to test assumptions made (internal validity) and estimated costs were 
compared with previous findings in the published literature (external validity).   
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5 RESULTS AND DISCUSSION 
 
5.1 COST-EFFECTIVENESS OF HPV TRIAGE FOR FOLLOW UP OF WOMEN 
WITH MINOR CYTOLOGICAL ABNORMALITIES (PAPER I) 
 
5.1.1 Cost effectiveness results 
 
Given that the Swedish society accepts and is willing to pay the additional cost, colposcopy 
with biopsy as follow-up and management of women with index smear diagnosis of ASCUS 
or LSIL was considered a cost-effective option, in comparison to HPV triage and repeat 
cytology. For women 30 years and older with index smear diagnosis of ASCUS, HPV triage 
was the least costly alternative in comparison to both strategies although with equal health 
effect as repeat cytology.  In the same index cytology and age group, colposcopy with biopsy 
detected 88 more CIN2+ cases per one thousand women with a cost-effectiveness ratio of 
SEK 2 056 per additional health effect compared with HPV triage.  
 
For women with index smear diagnosis of ASCUS and LSIL considered as one group, from 
30 years and older, HPV triage detected 11 more CIN2+ cases per one thousand women, and 
was less costly in comparison to repeat cytology. For women with index smear diagnose of 
LSIL from 30 years and older, HPV triage detected 15 more CIN2+ cases per one thousand 
women and was only slightly less costly in comparison with repeat cytology. For women 
below the age of 30 years, regardless of index cytology, HPV triage was the most costly 
follow-up strategy, although with equal or higher health effect than repeat cytology. For 
women with index smear diagnosis of ASCUS and LSIL considered as one group, in all 
ages, HPV triage was more effective than repeat cytology detecting 45 more CIN2+ cases 
per one thousand women, although more costly. 
  
When comparing HPV triage with immediate colposcopy with biopsy, we found that for 
women with index smear diagnosis of ASCUS and LSIL considered as one group in all 
ages, HPV triage was less effective detecting 40 less CIN2+ cases per one thousand women 
and more costly. The largest difference in costs between these two strategies was seen for 
women with index smear diagnose of LSIL below 30 years of age, where HPV triage was 
SEK 1 098 more costly and detected 17 less cases of CIN2+ per one thousand women. The 
smallest difference in costs was seen for women with index smear diagnose of ASCUS for 
women in all ages, where HPV triage was only  SEK 106 more costly than colposcopy with 
biopsy, although detecting 77 less CIN2+ cases per one thousand women. 
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Table I.2 Cost-effectiveness results for the follow-up strategies in different subgroups 
according to index cytology and age. 
Follow-up strategy Costa 
(SEK) 
Incremental 
Costa(SEK) 
CIN2+  
cases  
detecteda 
Incremental 
Effectivenessa 
Incremental  
Cost Effectiveness  
Ratioa, b, c 
ASCUS/LSIL 
All women 
     
Colposcopy with biopsy 2 432  215   
Cytology 2 928 496 130 - 85 Dominated 
HPV triage 3 057 625 175 - 40 Dominated 
      
 <30 years       
Colposcopy with biopsy 2 432  231   
Cytology 2 959 527 115 - 115 Dominated 
HPV triage 3 427 995 205 -   26 Dominated 
      
>30 years      
Colposcopy with biopsy 2 432  202   
HPV triage 2 765  333 152  - 51 Dominated 
Cytology 2 904  472 141  - 61 Dominated 
 
ASCUS 
All women 
     
Colposcopy with biopsy 2 432  192   
HPV triage 2 538   106 115 - 77 Dominated 
Cytology 2 662   230 115 - 77 Dominated 
      
 <30 years       
Colposcopy with biopsy 2 432  167   
Cytology 2 856   424 112  - 55 Dominated 
HPV triage 3 085   653 111  - 56 Dominated 
      
>30 years      
HPV triage 2 251  118   
Colposcopy with biopsy 2 432   181 206     88 SEK 2 056 /CIN2+ casea  
Cytology 
 
LSIL 
All women 
2 562   130 118   - 88 Dominated 
Colposcopy with biopsy 2 432  224   
Cytology 3 039   607 136  - 88 Dominated 
HPV triage 3 272   840 200  - 24 Dominated 
      
 <30 years       
Colposcopy with biopsy 2 432  250   
Cytology 2 990    568 117 - 133 Dominated 
HPV triage 3530 1 098 233 - 17 Dominated 
      
>30 years      
Colposcopy with biopsy 2 432  200   
HPV triage 3 034    602 169  - 31 Dominated 
Cytology 3 084     652 154  -46 Dominated 
“The follow-up strategies are ordered by increasing costs. Incremental cost, CIN2+ cases detected 
(effectiveness) and incremental cost-effectiveness ratio (ICER) are calculated relative to the next 
less costly follow-up strategy. ICER is calculated according to the following equation: ICER = 
(Cost of screening strategy A – Cost of screening strategy B)/(Effect of screening strategy A – Effect 
of screening strategy B). Dominated strategies are those with higher costs and lower clinical 
efficiency than other strategies.” 
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Figure I.1. Decision tree. 
 
 
 “A simplified decision tree of follow up strategies presenting one thousand women in all 
ages with index smear diagnosis ASCUS/-LSIL built on data from one single trial by 
Andersson et al 2005. The outcome shown in the figure is the number of detected or missed 
CIN2+ cases for each of follow up strategy.”  
 
5.1.2 Sensitivity analysis 
 
According to the sensitivity analysis, the results were most sensitive to varying costs for the 
HPV test. For women with index smear diagnosis of ASCUS and LSIL considered as one 
group and for women in all ages, HPV triage was a less costly and next most effective 
follow-up strategy below SEK 231 for the HPV test cost and  below SEK 522 for women 
30 years and older, while repeat cytology was a dominated alternative in all variations. For 
women with index smear diagnose of ASCUS considered as one group and all ages, HPV 
triage was the less costly below SEK 749, and below SEK 1 035 for women 30 years and 
older.  
 
5.1.3 Discussion 
 
At the time of this study, the Swedish guidelines recommended immediate colposcopy with 
biopsy as follow-up of ASCUS and LSIL/CIN1 for all women below the age of 35 years 
and HPV triage for women 35 years and older. Repeat cytology with Pap smear was not a 
recommended follow-up strategy due to a low sensitivity to detect CIN2+. However, repeat 
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cytology is still practiced as a follow-up method by either midwife at local outpatient 
clinics or by gynecologists depending on county council residence. 
Previous research has shown that significant costs evolve from unnecessary follow-up of 
women at low or no risk of developing cancer since a large proportion of the women are 
healthy or LSIL with spontaneous resolution (222). Therefore HPV triage could be 
considered a less aggressive approach for follow-up. Only women with persistent infections 
of HPV should be further examined with less aggressive protocols which are adapted to the 
actual risk of developing CIN3 or cancer (223). However, there are concerns of compliance 
to screening protocols regarding over and under screening, the association to SES and 
especially for cytology negative and HPV positive women. Anxiety induced of a HPV 
positive and cytology negative result when there is no immediate need for follow-up could be 
influence by SES and knowledge of HPV. In a previous study, results showed that women 
preferred immediate colposcopy instead of continued follow-up with HPV testing (177). SES 
and knowledge about HPV could possible influence compliance to putative screening 
algorithm.  
This study is based on data from a clinical trial and one important limitation with use of 
clinical trial data is their short duration. It is important to consider long-term consequences 
when assessing the cost-effectiveness of a screening strategy. This patient population is at 
risk of over-diagnosis and overtreatment; moreover, adverse events may occur. Such 
concerns should be monitored for a longer time period. However, no modeling studies 
concerning long-term risk of adverse events have yet been published.  
It is important to assess the relevance of the alternatives used in the model. When Paper I was 
written, women with index smear diagnosis of ASCUS and LSIL were commonly followed 
up by repeat Pap smear performed by a midwife/gynecologist or in some county councils 
such as Stockholm, by immediate colposcopy with biopsy. Based on previous research in 
population-based clinical trials (224) HR-HPV testing was considered to be a future 
alternative for follow-up (secondary screening). Comparison of these alternative follow-up 
methods was therefore highly relevant for economic evaluations being valuable material for 
making informed decisions about choice of follow-up procedures within the organized 
screening program.  
Recently, triage of ASCUS using HR-HPV testing showed high sensitivity for detection of 
CIN2+ and a high negative predictive value after 3 years of follow-up (225). Internal validity 
of the clinical trial was high since the study sample was based on CIN2-3, the clinical cut-off 
for treatment of precancerous lesions, and generated a large outcome in a relatively small 
study population. However, in this clinical trial, performance of Hybrid Capture 2 (HC2) was 
low compared with other studies (90, 201). The uncertainty of the parameters regarding test 
performance was therefore evaluated using data on HC2 from the previously mentioned 
Meta-analyses. However, the overall cost-effectiveness results did not change.  Nevertheless, 
external validity and generalizability to other settings is high since the alternative strategies 
are currently practiced in countries with organized screening programs.  
Choice of perspective determines which costs and health benefits to include in the analysis. 
This study was performed from a Swedish health care perspective and only included direct 
medical costs. However, a broader perspective (societal perspective) that includes all costs is 
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recommended for economic evaluations to assist decision-making on the societal efficiency 
in the allocation of health care resources. Also, cervical cancer have a broad impact on a wide 
range of personal and individual dimensions such as women’s health, the quality of life, work 
ability, social and sexual relations, physical function and income level which should all be 
considered in health economical evaluations. However, even though this study uses a 
narrower perspective (health care perspective), for countries with similar organized screening 
as in Sweden, it provides important information for decision-makers about issues regarding 
costs and effects when they consider whether to include HR-HPV DNA testing in current 
follow-up strategies. All direct medical costs for the follow-up strategies under comparison 
were based on Patient-level Clinical Costing (known as cost per patient (KPP) in Sweden), a 
methodology used to calculate the cost of each hospital stay or office visit for the individual 
patient. The method describes healthcare consumption from the perspective of diagnosis and 
is useful for decision making at all levels in the Swedish healthcare sector. This includes 
variable costs (costs related to time required for healthcare professionals and equipment), and 
fixed or overhead costs (e.g. costs for power, heat, rent and capital). However, these costs 
only reflect the estimated costs for the hospital environment, while excluding outpatient 
costs. The costs may therefore be overestimated compared with follow-up care provided in 
the outpatient setting. Thus, throughout Sweden follow-up and treatment is often provided in 
the hospital setting, rather than in outpatient clinics.   
Regarding effect data, use of sensitivity and specificity to detect CIN2+ lesions, is relevant 
and mandates follow-up in order to minimize the risk of developing invasive cervical cancer. 
Requirements for HPV triage to be an appropriate follow-up strategy of women with ASCUS 
and LSIL are high sensitivity and negative predictive value to detect CIN2+. Today, Swedish 
guidelines recommend use of HPV triage on women with minor cytological abnormalities 
(ASCUS and LSIL/CIN1) from age 35 and older. In our study all women in all ages were 
referred for colposcopy and biopsy. Results confirmed previous study results that HPV triage 
is not cost-effective under the age of 35. Results showed that HPV triage is dominated by 
immediate colposcopy and biopsy in all age groups and index cytology except among women 
over 30 years with ASCUS.  For women with LSIL, regardless of age, HPV triage was not 
considered a cost-effective alternative. The clinical trial found that HC2 testing detected 74% 
HPV positive women and 26% HPV negative women with index smear diagnose of LSIL 
which is low since only 5 to 10% are estimated to be negative for HPV infection according to 
previous research (201). The possible explanation for a larger percentage HPV negative could 
be explained by unadequate sampling, an infection with non-oncogenic HPV not targeted by 
HC2, false positive results or false negative HPV tests and spontaneous resolution. Today, 
both European and American guidelines do not recommend HPV triage for women with 
LSIL but of women with ASCUS. However, when deciding up on revised guidelines for 
referrals of women with ASCUS or LSIL to colposcopy and biopsy one should consider the 
recent Cochrane review presenting significantly higher sensitivity for HC2 to detect CIN2+ 
and CIN3+(108).   
To deal with the uncertainty in the costs and consequences addressed by this study we 
performed a one-way sensitivity analysis to examine when HPV triage becomes a cost-
effective alternative. When varying parameters for the follow-up strategies, the model result 
was most sensitive to changes in cost for the HPV test. A one-way sensitivity analysis could 
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be an inadequate approach due to overall uncertainty in the cost-effectiveness ratio depending 
on the combined variability of several variables. However, this analysis only used a few key 
variables in the base case and therefore a one-way analysis was assumed to be adequate to 
address uncertainty in this study.  
In this evaluation, all HR-HPV-positive women were assumed to be referred for colposcopy 
with biopsy. By only targeting women with the most oncogenic HR-HPV types, HPV-
genotyping could further reduce the number of women referred for colposcopy with biopsy. 
Moreover, with a higher performance of HR-HPV testing and reduced referral rates for 
colposcopy with biopsy, HPV ‘reflex genotyping’ could also become a cost-effective 
alternative follow-up strategy in the Swedish organized screening program. However, this has 
yet to be further evaluated. 
HPV triage was according to this study result a preferred follow-up strategy compared with 
repeat cytology for follow-up of ASCUS and LSIL among women 30 years and older.  With 
use of liquid-based cytology instead of repeat Pap smear within the organized screening 
program, HPV testing can be performed on existing sample (HPV reflex testing) which 
avoids the costs for an additional physician visit and could therefore be a cost-effective 
alternative to HPV triage. However, results from one study concluded that HPV triage with 
“two follow-up visits” (as in our study), was cost-effective compared with repeat cytology 
and immediate treatment (226). According to results from another cost-effectiveness study 
showed contrary results, that HPV reflex testing was a more effective and less costly strategy 
than HPV triage (with two follow up visits), repeat cytology and immediate colposcopy 
initially diagnosed with ASCUS (227). Similar results were also found in other cost-
effectiveness analyses that  HPV reflex testing in cases of ASCUS, was cost-effective in 
women of all ages (228, 229).  
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5.2 COST-EFFECTIVENESS OF HPV SELF-SAMPLING WITHIN THE 
FRAMEWORK OF THE ORGANIZED SCREENING PROGRAM (PAPER II) 
5.2.1 Cost-effectiveness result 
The overall projected model outcome showed that the cost effectiveness ratio for the 
combination strategy, depending on time interval between the screening opportunities ranged 
between; “€43 000 to €180 000 per LYG without the cost of added life-years, and between 
€74 000 and €206 000 with the costs of added life-years”.  The cost-effectiveness ratio for the 
combination strategy at a 5-year time interval, both with and without the cost of added life-
years, were beneath the chosen threshold value , indicating that this is a potentially cost-
effective screening approach compared with conventional cytology, status quo strategies and 
the alternative of no screening .  
Figure II:1. Cost-effectiveness result of different screening strategies at different 
intervals. 
 
 
 
Figure legend: “Cost-effectiveness of different screening strategies at different screening 
intervals: base-case analysis without the cost of added life-years.” 
 
5.2.2 Intermediate outcomes 
The model projected a reduction of the cervical cancer risk of 56% with the combination 
strategy at a 5-year interval, and 75% at a 3/5-year interval. For the status quo strategy with a 
3/5-year interval the reduction was 48% which is similar to results presented in other studies 
that performed model projections of HPV testing vs. cytology testing (228, 230). The model 
projections of intermediate outcomes of age-specific HPV prevalence among the group of 
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women with normal cytology test result peaked at 27% at the years near the age of 20 years. 
From an age-specific standpoint, peak prevalence of cervical dysplasia was almost 4% at the 
age of 34, with a second peak at age 43 of around 3%.  Our model projected an average 
prevalence of cervical dysplasia similar to the prevalence previous reported in a Swedish 
population (224), and in a clinical study population (114). The rate of cervical dysplasia 
detected by screening according to the status quo strategy was similar to rates shown in a 
previous report from Sweden (231). Referral rates for colposcopy and biopsy without 
findings of cervical dysplasia or cervical cancer were 35% higher for the combination 
strategy using a 3/5-year interval compared with a 5-year interval, which is similar to results 
presented in another study (232). 
 
Table II:2. Average life time cost, life time expectancy (discounted at 3% and 
undiscounted, reduction on cervical cancer risk and ICER (€)/LYG. 
Screening strategy
 
Average 
lifetime 
cost (€) 
LYG, d 
3%
a 
LYG,  
0%
a 
CC 
risk, % 
ICER, 
€/LYGb,d,e 
ICER with 
cost 
of added  
life-years,  
€/LYGc,d,e 
No screening  303 28.7135 65.6275 — — — 
Combination strategy, 5-y  1 151 28.7331 65.7108 56.0 43 000 74 000 
Status quo strategy,3/5-y  1 294 28.7340 65.7128 48.1 Dominated
e
 Dominated
e
 
Conventional cytology, 3-y  1 334 28.7344 65.7111 50.3 Dominated
e
 Dominated
e
 
Combination strategy, 3/5-y  1 561 28.7380 65.7259 75.4 84 000 112 000 
Combination strategy, 3-y  1 589 28.7381 65.7299 76.8 Dominated
e
 Dominated
e
 
Conventional cytology, 2-y  1 743 28.7377 65.7306 65.1 Dominated
d
 Dominated
d
 
Combination strategy, 2-y 1 918 28.7400 65.7374 85.1 180 000 206 000 
” aTotal discounted and undiscounted health effects is presented as life expectancy between 
age 15 and age 85 years, defined as LYG. 
b
The ICER for a given screening strategy was 
calculated relative to the next most effective strategy after eliminating dominated strategies 
expressed as € per LYG. cICER with the inclusion of cost of added life-years. Strategies that 
are dominated are more costly and less effective than another strategy. 
d
Strongly 
dominated strategy (i.e., strategy that were more costly and less effective than others). 
e
Weakly dominated strategy (i.e., strategy whose costs and benefits were improved by a 
mixed strategy of two other alternatives).”  
 
5.2.3 Sensitivity analyses 
 
Results were most sensitive to changes in the accuracy of the test used in the different 
screening strategies and their associated costs and least sensitive to variation in costs for 
treatment of cervical cancer. However, under most variations of model parameters and 
additional scenario analyses, the combination strategy at a 5-year time interval remained 
cost-effective. 
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5.2.4 Discussion 
 
Self-sampling eliminates the need for a visit to a clinic, and enables genotyping, which 
makes the practice less aggressive than a gynecologic examination offered to all women 
with test results showing any abnormality, which is associated with high direct medical 
costs, direct non-medical costs and indirect costs (data shown in Paper III and Paper IV). 
Also, negative physical and psychological effects are associated with a more aggressive 
approach (233, 234). However, for self-sampling performed by the women themselves to be 
successful, the acceptability among the population must be high and they must comply with 
screening recommendations. One study found that more than half of the women in the study 
group (61%) preferred self-sampling at home instead of clinic based screening as long as  
self-sampling taken by the women themselves  has the same health effect as a clinic-taken 
test, this due to greater ease and less inconvenience for the women in their everyday life 
(140). 
  
Previous research has indicated that HR-HPV self-sampling performed in the privacy of the 
home is a feasible alternative for non-participants in clinic-based screening programs, the 
“hard-to-reach” women and women generally reluctant to undergo vaginal examination (109, 
110).  Overall, it could potentially increase the participation rate of organized screening 
(111).  However, European and international guidelines do not yet recommend self-
sampling in organized screening. This due to lack of evidence of higher accuracy, or as 
high accuracy (sensitivity and specificity) with self-samples performed by the women 
themselves than with samples taken by a clinician among today’s available HR-HPV self-
sampling tests. According to a recent Meta-analysis of almost 40 studies with data from 
approximately 150 000 women found that average sensitivity for detection of CIN2 was 76% 
and for CIN3 84%, while specificity for CIN2+ was 86% and for CIN3+ 87% (113). Samples 
taken by a clinician showed overall higher accuracy than self-sampling performed by the 
women themselves.  HPV self-sampling using signal-based assays was both less sensitive 
and less specific than sampling by a clinician. However, some PCR-based (polymerase 
chain reaction, a technology that selectively amplifies a target sequence of DNA) HPV tests 
showed similar sensitivity between samples collected by the women themselves and those 
taken by a clinician. Overall conclusions from the Meta analysis were therefore, that 
organized screening programs that intent to use signal-based assays (cell-based assays) 
should preferably be taken by a clinician. Some PCR-based HPV tests could however be 
considered after thorough pilot studies to assess feasibility. Present study was modeled 
based on accuracy data from a study examining HR-HPV among women, using PCR-based 
HPV tests (114-116). Regardless of sample technique, the feasibility of HPV testing for use 
in primary screening has been subject to discussion mainly because of its overall low 
specificity when used as a single HPV test, especially among young women, where HPV 
testing could lead to over-diagnosis of regressive CIN2 (104). Result from the clinical study 
found that repeat HR HPV testing at short intervals increased specificity for detection of 
CIN2+ lesions from about 94.2% to 97.8%. Due to lack of data from large-population 
based studies on accuracy of self-sampling by the women themselves vs. samples taken by 
a clinician and compliance with screening based on self-samples, this study made necessary 
assumptions of compliance rate and follow-up of HPV positive results. This has yet to be 
examined in real-life settings before deciding up on reframing the organized screening 
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program for cervical cancer. However, primary HPV testing has proven more effective than 
primary screening with cytology in reducing both cervical cancer incidence and mortality (88, 
91, 107). The risk of CIN3 or cervical cancer is lower 5 years after a negative HPV test than 3 
years after a negative cytology test, thus the HPV test has a higher NPV (92). This altogether 
implies the need for further clinical studies and health economic evaluations of available self-
sampling tests within the framework of the organized screening program. 
 
According to Briggs et al. (2001), every economic evaluation is subject to  degrees of 
uncertainty or methodological controversy arising from discordant analytical results, data 
requirements, need to extrapolate results over time and a desire to generalize results to other 
settings (55, 70). Choice of modeling technique and model structure depends on availability 
of data for the analysis. Preferable, a systematic review of the literature should be conducted 
to decide up on data of importance for inclusion to the model. Due to lack of data on test 
accuracy, compliance with self-sampling within the framework of organized screening and 
the natural history of HPV, cervical dysplasia and cervical cancer, as well as survival from 
cervical cancer (long-term research), no specific rules were applied for inclusion or exclusion 
of data. Instead, best available published data appropriate for the model was initiated and 
decided up on within the group of clinical experts and co-authors in this study. The validity of 
the model was then tested by controlling for the primary and intermediate outcomes projected 
by the model.  The “do-nothing” alternative (i.e. no screening and cervical cancer is only 
detected by symptoms) was applied to validate the primary and intermediate outcomes of the 
model.  Regarding the primary outcomes, the age-specific incidence rate of HPV infection 
applied into the model were varied within a plausible range and computed the Markov 
model so that the projected outcome result resemble the average annual cervical cancer 
incidence rates by 5-year age groups before screening was initiated in Sweden, and thereby 
constructed the reference strategy “no screening”. The cytology-based screening strategy 
was then applied and model projected outcomes were close to empirical data after 
implementation of the cytology based screening program until 2009. Moreover, important 
intermediate projected outcomes were age-specific HPV prevalence among women with 
normal cytology test age-specific peak prevalence of CIN; HPV prevalence in older women 
all of which was similar  in previous clinical trial studies and observed in a Swedish 
population (114, 224, 235). The referral rate for a gynecological examination with 
colposcopy and biopsy without presence of cervical dysplasia was 35% higher for the 
combination strategy at the 3/5-year interval compared with the fixed 5-year interval which 
is similar to the results from another model projection (232). Additionally, outcome model 
parameters were varied within relevant range in the sensitivity analyses and additional 
alternative scenarios were applied to explore the impact on cost-effectiveness. However, 
according to the results from the sensitivity analyses, the combination strategy at 5-year 
intervals remained a cost-effective alternative while other follow-up strategies remain 
dominated.  
 
Overall, our model projected outcomes showed that the combination strategy with a 5-year 
time interval is potentially cost-effective compared with current screening practice and no 
screening when using a commonly used threshold value (€80 000). Even though model 
studies are simplifications of real-life settings, the alternative comparison with conventional 
cytology reflects current screening practice in real-life settings in accordance with the 
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aforementioned flowchart. Moreover, the follow-up and treatment of cervical dysplasia and 
cervical cancer associated with both alternatives also reflect the real-life setting. A transition 
to HR-HPV DNA testing is underway in Europe and research on the feasibility of HPV self-
sampling and evaluations of their consequences on costs and value of health gains are of 
relevance for making informed decisions about a revised organized screening program for 
current and future generations in need of screening to prevent cervical cancer.  
 
Few other studies compare self-sampling with conventional cytology and no such comparison 
has as yet been made within the framework of organized screening programs. One study, 
similar to ours, based on a US clinical trial evaluated the cost-effectiveness of self-sampling 
performed at home and found that in combination with follow-up of HPV positive women by 
use of  clinical based cytology was cost-effective in comparison to clinic-based cytology 
screening alone (48). Our study indicated that the combination strategy at 3/5-year intervals 
and at 5-year intervals was cost-effective, in accordance with previous studies on clinic-based 
HPV testing, though not involving self-sampling at home (135, 228, 230). One study argued 
in favor of HPV testing in primary screening (138). Our own previous cost-effectiveness 
study (Paper I) found that HPV triage was superior to cytology screening for management of 
women aged 30 years and older with initial diagnose ASCUS. Regarding number of 
screening opportunities throughout a woman’s lifetime, one study in a Swedish setting 
concluded that HPV testing combined with cytology on three occasions during a lifetime was 
optimal (236). In our study, lower referral rates were associated with a 5-year screening 
interval than with a 3/5-year interval. These findings are similar to the results of other studies, 
indicating that less frequent screening could reduce unnecessary follow-up and treatment and 
provide cost-savings with equal or more effective outcomes (232, 237, 238).  
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5.3 BARRIERS TO AND FACILIATORS OF COMPLIANCE WITH CERVICAL 
CANCER SCREENING (PAPER III) 
 
5.3.1 Sociodemographic characteristics 
According to the results on the sociodemographic characteristics of the 1510 respondent 
women in the study, few were associated with low SES. A comparison with the general 
female population in Sweden showed that a significantly higher proportion (p <.01) of 
respondents had an education level above high and higher income level. 
 
5.3.2 Time and travel cost and other direct non-medical costs 
The estimated average waiting time was 10 minutes and the procedure time was 13 minutes, 
for a total time at the outpatient clinic of 23 minutes. Average travel time to the outpatient 
clinic was 18 minutes and 26 minutes from the clinic, for a total travel time of 44 minutes. 
Over half the women (53%) reported officially taking time off work to attend screening, with 
a mean time of 2.5 hours. Among all women, approximately 12% were accompanied by a 
companion to attend screening, the majority by their partners. Among all companions, almost 
60% had taken time off work, an estimated mean time of almost 2 hours. Among all women, 
almost 3% had arranged for childcare. Paid childcare was estimated with a mean time of 
almost 3 hours for an estimated cost of approximately €78. Overall mean total cost per 
attendance, including a companion, if any, was almost €56. 
 
5.3.3 Compliance 
In all, 44% of women stated that they were unlikely to attend screening within one year of the 
initial invitation (noncompliers), 51% of whom stated that they could not take time off from 
their jobs, while 33% stated they were too busy and 16% cited other reasons. Qualitative data 
from responders indicated that other reasons could include fear of gynecological 
examinations, postponing the visit due to menstrual period, pregnancy at the time of the 
invitation and more.  
 
5.3.4 Knowledge of HPV 
 
In all, almost 70% of respondents knew that screening was meant to prevent cervical cancer, 
while 30% believed that cytology testing was used to screen for all or other gynecological 
cancers. Almost half of the respondents were satisfied with the invitation letter while almost 
30% were unsatisfied and others were either partly satisfied or answered “don’t know”. 
Compared with women aged 30-49 years, a significantly higher proportion of women aged 
29 years or younger knew that HPV is sexually transmitted (51% vs 39%), that both men and 
women can be infected (30% vs. 24%) and that HPV is most common among young adults 
(37% vs. 27%). Women aged 29 years or younger also knew that HPV infections often had 
no symptoms (41% vs 35%); that persistent HPV infection may lead to cervical cytological 
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abnormalities (54% vs 48%); and were more aware that HPV can cause genital warts (24% vs 
22%). Of all women in the study group, 64% knew that an HPV vaccine is available, but 
fewer were aware that the vaccine is most effective if administered before sexual debut (41%) 
and that the vaccine does not protect against all HPV types, therefore making it important to 
continue to attend screening (34%). However, only 7% believed they had a good knowledge 
of HPV and cervical cancer, and only 16% felt they had a good knowledge of HPV and 
cervical cancer prevention. A majority of women (63%) expressed a desire to learn more 
about HPV infection, risk factors and prevention from a midwife or physician, while 52% 
wanted additional information from brochures.  
 
 
5.3.5 Factors associated with compliance and knowledge of HPV 
Age, education, and income were the most important correlates of HPV knowledge and 
compliance; and additionally factors for compliance were time off work, companion and 
HPV knowledge. Women that took time off work to attend screening were less likely to be 
compliant with screening within one year from initial invitation. Moreover, women with 
knowledge of HPV were more likely to comply with screening.  
 
5.3.6 Discussion 
This descriptive study investigated barriers that may hinder participation in health-promoting 
behavior, since perceived benefits must outweigh perceived barriers in order for behavior to 
change. With continuous pressure on efficient allocation of health care resources to maximize 
health outcomes, decision-makers are concerned about ensuring that both the clinical 
effectiveness  and cost-effectiveness of preventive health care are continuously evaluated 
(239). More often, direct-medical costs are used in health economic evaluations while direct 
non-medical and indirect costs less frequently are included and often overlooked (240). 
However, a societal perspective (i.e. a broader perspective) is recommended to assess the 
cost-effectiveness of treatments or preventive measures in health care (55). By using a 
societal perspective including direct medical costs, direct non-medical costs and indirect 
costs, the risk of sub-optimization decreases compared to if the analysis was carried out from 
a more restricted perspective. Therefore, use of societal perspective in health economic 
evaluations where costs incurred by different agents are included and compared is a preferred 
option.  Important is therefore to identify all possible costs incurred by attending a clinic-
based screening visit.  
Moreover, indirect costs and direct non-medical costs may affect compliance with preventive 
health services such as screening.  Since the effectiveness of a cervical cancer screening 
program crucially depend on women’s attendance or compliance, these factors are highly 
important to identify. The literature suggests that high prices or time and travel costs deter 
purchase or use, while low prices encourage adherence to recommended preventive health 
services (174). Overall it should be acknowledged that even when a preventive health system 
offers free screening, all eligible individuals will incur costs for time and travel that are not 
reimbursed by public funds. Depending on their terms of employment, individuals may lose 
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income due to absence to attend screening and if they perceive their time and travel costs as 
high, they may choose not to attend screening (241-243) . In Sweden today, copayment for 
screening services ranges from zero to about €22, depending on county council of residence. 
However, even when screening is offered free of charge, women will still consider the 
necessary time and travel costs, as well as other direct non-medical costs, which may deter 
them from using screening services. The importance of cost in relation to screening 
compliance was shown in 2003 when Stockholm introduced a screening fee of €14 per visit, 
resulting in a 23% decline in the attendance rate, which then recovered after the fee was 
discontinued (244). A disproportionate number of women in our study were high income 
earners compared with the eligible screening population at large, possibly indicating that 
women with lower incomes perceive their time and travel costs as being relatively higher, 
which may deter screening. Moreover, a large proportion of all responders were 
noncompliers, of whom many cited difficulties taking time off work. This may also imply 
that the disproportionate number of women with high income and high educational level in 
our study also perceive their time and travel costs as high, for which reason they choose to 
attend at a later time or when convenient in everyday life.  
Other studies support our findings that indirect costs and direct non-medical costs are 
significant in relation to direct medical costs (242, 245).  Our study concluded that mean 
costs per attendance were somewhat higher in this study than in another study of clinic-based 
cervical cancer screening in the UK (246). This difference may be explained by a longer 
average time for the clinical visit and the fact that more women took time off work. 
Moreover, leisure time was valued at about half of our estimate. If our analysis were carried 
out using their value for leisure time and excluding the extra cost of time off work beyond the 
estimated time for travel and the screening visit (approximately 1 hour), our study presented 
similar cost estimates.  This highlights the importance of context-specific calculations when 
estimating indirect costs and direct non-medical costs. Women attending with a companion 
and women who arranged for paid child care substantially increased mean costs. The choices 
to be accompanied by a companion and child care are not addressed by our data, but these 
factors have an important impact on cost.  
Use of self-sampling could reduce overall sampling costs but also affect coverage (158, 173, 
247). HPV self-sampling as alternative screening, with no costs for time and travel, may 
increase compliance among those women who perceive time and travel costs to be high. Use 
of HPV test enables longer time intervals between screening since it the risk of developing a 
CIN3 or cancer after five years is lower after a HPV negative test result than a negative Pap 
test.  The longer time intervals between screening opportunities enabled by HPV testing will 
affect the population coverage by changes in the definition of test coverage. Also, longer 
screening intervals can increase the coverage for the hard-to-reach women and an under 
screened population and also acceptable to a disadvantaged group of women (170, 173, 248-
254). In Sweden, Uppsala County Council has successfully increased overall participation in 
the screening program by introducing a self-sampling device as an alternative screening 
method (110, 114). One study in the Finnish cervical cancer screening programme involving 
non-participants showed that HPV self-sampling could lead to higher participation rate and 
protective effect among those women (255). However, there is also a concern (mostly 
speculative) that use of HPV tests will affect the women´s behavior and attitudes towards 
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screening. Suggested is that the longer interval may impact on women’s behavior and 
therefore have a negative effect on coverage and especially among women with low SES 
(248).   However, information on cues to action, necessary for prompting engagement in 
health-promoting behavior, particularly in regard to the uptake of screening with self-
sampling is lacking and further research on this is needed. 
HPV-self sampling may be a preferred option specifically in low-resource settings where 
there is restricted infrastructure which lowers the effectiveness of clinical based-cytology 
screening programmes. This due to the fact that women in these settings will be screened 
only a few times in their lives and the high sensitivity of a HPV test is important. Although, 
there are concerns about women not receiving the home-mailed self-sampling devices due to 
different reasons either in mailing lists or logistic reasons (173, 250).  The effectiveness of 
self-sampling depends heavily on updated and correct register data. However, use of this 
method in countries with well-organized screening programs, such as Sweden, could possibly 
increase access to screening both for those reluctant to undergo a gynecological examination 
and women “hard to reach” and thereby improve the overall participation and the inequitably 
among women with low SES.   
According to previous research, women with low education level or SES and certain 
disadvantaged ethnic groups are less knowledgeable about HPV infection and associated 
risks of developing cervical dysplasia and cervical cancer (256-259). In European countries, 
studies have shown that women with higher educational level were more knowledgeable of 
HPV than those with lower educational level and an association with SES (150, 151). Many 
of the studies that have been conducted were performed before the introduction of the HPV 
vaccine (before 2007-2009). Knowledge of HPV has most likely increased since then. Also 
possible is that women with lower educational level could have increased their knowledge far 
more than women with higher education. Previous studies on awareness and knowledge of 
HPV in Europe since the introduction of the mass vaccine have shown various results on 
knowledge and attitudes towards vaccination. One study found that knowledge about 
cytology with Pap smear were higher than knowledge about HPV test but still a large 
proportion knew about the transmission of viruses, HPV and its relation to cancer (260).  This 
study also found that women with higher educational level were more knowledgeable of 
cervical cancer, prevention methods and HPV. However, attitudes towards HPV vaccination 
were alike among all women regardless of educational level. In our study, women with low 
SES was less represented however there was a clear association between HPV knowledge 
and education level. Women with higher education were more knowledgeable about HPV 
than those with lower education level.    
Additionally; age was also one of the most important correlates of HPV knowledge. Most 
importantly, we found that young adults were more familiar with HPV than older women; 
they knew more about HPV prevention methods, including HPV vaccination, even though no 
statistical difference was found between the age groups. This implies that inclusion of HPV 
vaccination in the school vaccination program may have an impact on the level of knowledge 
about prevention in both younger and older age groups. Earlier targeted information and 
commercial campaigns prior to this study may have increased knowledge of HPV, but to 
what extent is unclear.  
 72 
In our study, a majority of women wanted information about HPV and preventive methods to 
be provided by through personal counseling by a midwife or physician. Previous research 
aiming to provide insight into effective communication tolls has shown that differences in 
knowledge about HPV decrease following any type of intervention or informative public 
campaign (261-265). However, further knowledge about effective communication tools and 
how to increase knowledge with populations about HPV is needed. Further, there is often an 
absence of information regarding SES in studies of effective communication tools. Further 
knowledge about SES and how to reduce the SES inequalities is therefore needed.  
In summary, the most important correlates for compliance were age, education, income, time 
off work and knowledge of HPV, while the most important correlates for knowledge of HPV 
were age, education and income. This suggests that knowledge of HPV and its relationship to 
cervical cancer promotes/facilitates compliance. Knowledge of HPV is a factor that can be 
directly assessed through public education using campaigns and personal counseling with the 
midwife or gynecologist.  
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5.4 COST OF PREVENTING, MANAGING AND TREATING HUMAN 
PAPILLOMAVIRUS (HPV)-RELATED DISEASES BEFORE THE 
INTRODUCTION OF QUADRIVALENT HPV VACCINATION (PAPER IV) 
 
5.4.1 Cost for screening, management and treatment of CIN and cervical 
cancer 
From a societal perspective, the estimated economic burden of cervical dysplasia was €75 
million, €8.5 million of which consisted of costs for colposcopy and biopsy referrals and € 6 
million of treatment costs. Based on data showing that 441 women in Sweden were 
diagnosed in 2009 with incident cervical cancer, and 9 651 prevalent cases and 158 women 
died from the disease costs for staging and treatment and follow-up of these cases resulted in 
an annual cost of €23 million, 20% accounted for palliative care. The economic burden 
attributable to HPV related diseases cervical dysplasia and cervical cancer was €98 million. 
 
5.4.2 Treatment patterns for genital warts 
The treatment patterns and percentage of patients with external, external and internal, or 
internal genital warts did not differ by gender. The majority of patients with incident external 
and external and internal genital warts received pharmacological treatment (topical creams), 
while the wait and see approach was assessed for the majority of patients with only internal 
genital warts. Overall, destructive treatment was more common among recurrent and 
persistent cases of genital warts in our study. Estimated mean time for office visits in the 
absence of destructive or surgical treatment was 22 minutes, and an estimated 31 minutes 
when destructive or surgical treatment was provided. The average number of visits needed for 
incident and recurrent patients with pharmacological treatment, destructive treatment, 
combination treatment, or surgical treatment was estimated at: 2, 2.5, 2.3 and 1.6, 
respectively. Based on data from a published study, he total number of incident cases of 
genital warts (seeking or receiving treatment) in Sweden was estimated to be 18 196 in 2009 
(220). Based on f data from the United Kingdom, there were an estimated 10 548 recurrent 
and persistent cases of genital warts in Sweden according to our extrapolation (221). The 
average estimated percentage of patients with external genital warts only was 87%, while 
10% had both external and internal genital warts and 3% internal genital warts only. 
 
5.4.3 Cost for management and treatment of genital warts 
 
The total cost of 28 744 cases of genital warts in 2009 was €9.8 million. The total annual cost 
of treating external genital warts was estimated at €8.1 million, while costs for external and 
internal genital warts were estimated at €1.2 million, and internal genital warts alone at €0.5 
million. Of the total cost, that of pharmacological treatments was estimated at €2.9 million, 
while destructive treatment was €3.4 million. Costs for surgical excision were €1.9 million 
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and combination treatment €0.9 million. The total cost of management and treatment of 
recurrent and persistent cases alone was €4.5 million. In the sensitivity analyses we lowered 
the direct costs for a visit to a physician and treatment by 50% to reflect possible outpatient 
costs. This decreased the total cost of treatment of genital warts by €3.8 million (39%). 
 
 
5.4.4 Total annual cost for cervical dysplasia, cervical cancer and genital 
warts 
 
The total estimated costs for the prevention, management and treatment of HPV related 
diseases namely cervical dysplasia, cervical cancer and genital warts for 2009 was €108 
million, and ranged from €66 to €121 million depending on sensitivity analyses. 
 
5.4.5 Discussion 
The number of cases of cervical cancer was obtained from the IARC. However no data are 
available on FIGO staging, whether patients had concluded treatment, relapses or survival 
rates related to various FIGO stages. To avoid duplication between cases, we considered 
only follow-up costs for prevalent cases and estimated treatment costs for new cases. 
Similar problems arise regarding the number of patients with cervical dysplasia and genital 
warts, for which register data are lacking or unavailable. Data inaccuracies or the need to 
make assumptions may have led to certain underestimation or overestimation of costs. 
 
When estimating treatment patterns for management and treatment of genital warts, the 
clinical expert panel was asked to answer based on experience, rather than by referring to 
patient charts, which may have led to biased estimate of costs. Moreover, the estimated 
number of recurrent and persistent cases of genital warts was based on a UK publication 
(221). Swedish data would of course more accurately reflect the situation in Sweden, but no 
such data has yet been published. Furthermore, register data do not reflect nuances in 
treatment of genital warts. However, incidence rates are possibly underestimated  since 
primary cases that do not receive pharmacological treatment would not be included (220).  
 
Travel time to and from healthcare facilities was based on estimates from Stockholm (Paper 
III), which may not be representative of the entire country; costs may be underestimated for 
geographical areas involving greater distances and consequently more costs.   
However, our findings give important insight to HPV-related diseases in Sweden which has 
previously been unknown. Despite limitations of this study, these results are of interest due to 
the recent introduction of the quadrivalent HPV vaccination (against HPV6, 11, 16 and 18) 
program among school girls. In clinical trials, the quadrivalent vaccine has shown to reduce 
lifetime risk of cervical cancer caused by the corresponding HPV types by 47%-100%, 
depending on age (i.e.girls being HPV naïve when vaccinated) and coverage (266, 267), and 
to reduce the risk of genital warts by 83% (268). A significant reduction in the future 
economic burden of management and treatment costs for CIN, cervical cancer and genital 
warts is expected due to factors such as an unchanged organized cervical cancer screening 
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program and added quadrivalent HPV vaccination for young girls. Previous cost-
effectiveness analyses have shown that adding a quadrivalent HPV vaccine to an existing 
cervical cancer screening program is cost-effective (269-271). The WHO funded PRIME 
modeling study, found that in 156 of 179 countries, prophylactic HPV vaccination in girls, 
HPV naïve at onset of vaccination is very cost-effective (271). Sweden was, in spite of a 
relatively low incidence and mortality of cervical cancer, one of these countries. Important to 
consider were that the effects of genital warts were not taken into account in this analysis. 
However, further studies on the effect of HPV vaccine on other HPV-related diseases needs 
to be evaluated. Moreover, further modeling studies are needed to fully evaluate the cost-
effectiveness of the quadrivalent HPV vaccine and the upcoming nine valent HPV vaccine. 
The implementation of organized prophylactic HPV vaccination in Sweden may lead to an 
evolution where a greater portion of resources are allocated to prevention and a decreasing 
portion allocated to manifest disease management.  
Questions that remain to be answered is whether boys be included in the organized HPV-
vaccination program, and how to wisely design the Swedish cervical cancer screening 
program to adapt to a future generation women with a lower incidence and prevalence of 
precancerous lesions and genital warts. With the future implementation of a nine valent 
vaccine, expected reduced incidence of cervical cancer will lead to a situation of cervical 
cancer being a rare disease while other HPV related diseases such as tonsillar carcinoma is 
expected to increase, and especially among men (272). Hammarstedt et al demonstrated the 
increasing incidence and the proportion of HPV-positive tonsillar cancer and authors 
hypothesized an “epidemic” of HPV-infection in the oropharynx (273). Although this study 
only assessed few of the HPV-related diseases, these diseases account for a majority of the 
total economic burden attributable to HPV type 6, 11, 16 and 18 infections this study gives 
important information on the potential savings if these major diseases were eradicated in the 
future.  Moreover, costs from this study may be incorporated into future cost-effectiveness 
analyses comparing strategies with different available HPV vaccines, and alongside the 
existing and a potential revised cervical cancer screening program including HPV tests. 
 A recent study from Italy concluded that the estimated economic burden for 9 HPV related 
diseases namely cervical cancer, cervical dysplasia; cancer of the vulva; vagina; anus, penis, 
head and neck; genital warts and recurrent respiratory papillomatosis were a total of €529 
million (with a plausible range of €480-€686 million) (expressed in 2011 Euro) of which 
HPV types 6, 11, 16 and 18 accounted for 55% of the total cost (274).  In the Italian study, 
only direct medical costs were included from the perspective of the National Health Service. 
Of the total sum, €147 million represented direct medical costs for cervical conditions alone. 
Also, the economic burden of non-cervical, HPV-related diseases born by men were 
identified as cost drivers highly important to consider when deciding up on future preventive 
programmes to further reduce HPV prevalence among the population. This study highlights a 
significant economic burden associated with the most prevalent HPV-related diseases in Italy. 
However, similar estimates are expected in every country with similar health care system and 
preventive health care programs for cervical cancer.  Our study only provides a partial 
estimate of the cost of HPV-related diseases. Other HPV-related diseases were not included 
and have yet to be further evaluated.  
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The economic burden of cervical cancer and genital warts is somewhat higher than found by 
other studies carried out in Europe (275) (276, 277).  However, similar estimates were made 
in Belgium, where estimated annual screening costs from a societal perspective were almost 
€65 million with an additional 16 million for management of cervical cancer, cervical 
dysplasia and genital warts (10.5 million inhabitants) (278, 279). The differences of unit costs 
across countries may be related to possible overestimates in the present study. First, direct 
medical costs for an initial visit for cytological testing reflected the costs for a hospital of 
which the aforementioned studies reported half of the direct medical cost for a Pap smear 
visit. Although when we decreased in the cost of an initial visit with 50%  
and number of colposcopy referrals reduced the total annual cost to similar estimations 
previously presented in the aforementioned studies. However, actual costs for a visit for  
medical procedure in an outpatient clinics has yet to be examined to accurately determine a 
possible lower cost. However, compared with other studies, the overall treatment costs for  
genital warts in our study were similar to those from other studies (280, 281). 
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6 CONCLUSIONS 
 
6.1 PAPER I 
 
In Sweden, approximately 650 000 cytology test are performed every year, of which around 
5% show any cytological abnormalities (80% are diagnosed ASCUS/-LSIL and 20% HSIL) 
and are in need for further follow-up and management. Our study result concluded that an 
additional 85 cases of CIN2+ could be detected per one thousand women with index smear 
diagnosis of ASCUS or LSIL per year if immediate colposcopy with biopsy was used for 
all of these women instead of repeat cytology. This translated into approximately 2 000 
additional CIN2+ cases detected compared with the use of repeat cytology. Compared to 
HPV triage, immediate colposcopy with biopsy would detect approximately 1 000 
additional CIN2+ cases. Alternative follow up strategy is especially important since an 
estimated 5 to 30% of missed CIN2+ cases could progress to invasive cancer. However, use 
of colposcopy and biopsy is a more aggressive approach which is associated with risk of 
over diagnoses and overtreatment of women not truly at risk of developing cervical cancer. 
Moreover there are concerns about adverse events which may apart from the physical and 
psychological distress have important economic impact that needs to be addressed. 
Therefore HPV triage could be considered a less aggressive approach. In this study, our 
results show that HPV triage is a preferred alternative follow-up strategy compared to 
repeat cytology for follow-up of index smear diagnosis of ASCUS/-LSIL among women 
over 30 years of age. For women 30 years and older with index smear diagnose of ASCUS 
alone, HPV triage was the least costly alternative with equal health benefits as repeat 
cytology. Current Swedish guidelines and practice for women with ASCUS/-LSIL/CIN1 
are HPV triage on women 35 years and older. Results from this study concluded that HPV 
triage is the least costly follow-up strategy among women 30 years and older with index 
smear diagnose of ASCUS, however the specificity of HC2 needs improvement. 
 
 
 
6.2 PAPER II 
The combination strategy involving use of cytology testing between the age 23 year and  
34 and thereafter HPV self-sampling performed by the women themselves at home with a  
5-year screening interval is potentially cost-effective compared with no screening, and  
with current screening practices when using a threshold value of €80 000 per life-year 
gained. With recent research showing that the risk of cervical pre-cancer is low up to 
5 years after a HPV  negative test, implies together with this study result that HPV testing in 
primary screening from 35 years and older could potentially be a both clinical effective and a 
cost-effective approach. Health care resources should preferably be allocated to women 
with HPV 16 and HPV 18 positive results which have the highest risk of developing cervical 
pre-cancer. Further pilot testing of HPV self-sampling tests and research on acceptance and 
compliance with self-samples in larger population based studies has yet to be performed to 
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make better-informed decisions on reframing the organized screening program.   
 
6.3 PAPER III 
We found that time and travel costs and other direct non-medical costs are substantial and 
may deter women from attending and may also influence the overall cost-effectiveness of a 
screening program.  A large share of the responders was noncompliers with screening within 
one year of the initial invitation. Knowledge was higher among women in the younger age 
groups. Age, education, and income level were the most important correlates of HPV 
knowledge, while additional, hours off work, accompanying companion and knowledge of 
HPV were important correlates of compliance. Through public education programs, 
knowledge of HPV could be increased on population level and thereby promote/facilitate 
compliance with screening. Given that the effectiveness of a population based screening 
program depends on participation and compliance, both knowledge and low or no cost for the 
women to attend screening are both important factors that needs to be considered. All barriers 
for compliance with screening should be addressed and taken into account within the 
organized screening program.   
 
6.4 PAPER IV 
A cost-of-illness study estimates disease-specific costs, and provides information on the 
maximum potential savings that could be done if a disease were to be eradicated. From a 
societal perspective including both direct medical costs and indirect costs, we found that the 
estimated economic burden of HPV related diseases namely cervical dysplasia, cervical 
cancer and genital warts were a total of €108 million. Costs for screening, management and 
treatment of cervical dysplasia were €75 million of which costs for primary screening and 
inadequate tests alone accounted for the majority of this sum and management and follow-up 
of abnormal cytology results were estimated to account for around €11 million of the total 
costs while costs for treatment of CIN accounted for a minor cost. Estimated costs for 
recurrent and persistent cases of genital warts were around €10 million. In the sensitivity 
analysis, costs were most sensitive to variations in screening costs. This implies that any 
changes in the existing organized screening program may have large impact on the overall 
costs. The results provide an estimate of the significant economic burden imposed by three 
major HPV-related diseases; cervical dysplasia; cervical cancer and genital warts in Sweden. 
There should be further evaluations of the economic burden of the other HPV-related 
diseases; cancer of the vulva, vagina, anus, head and neck, penis and recurrent respiratory 
papillomatosis. Future evaluations should also consider both men and women to fully 
understand the cost drivers. 
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7 FUTURE RESEARCH 
 
Payers for health care are continuously searching for value for money from health care 
interventions, in an effort to achieve the best possible health and health care within available 
resources. Since there always will be more alternatives than resources will allow, choices and 
trade-offs needs to be made. Health economic evaluations are therefore important information 
to aid decision making about the allocation of resources to technologies. However, an 
important question for conducting economic evaluations if there is documented clinical 
evidence existing for the disease and alternative preventive methods and treatments. These 
data will assess the quality of the economic evaluation. Still there is knowledge gaps that 
need to be addressed in future research. 
 
Firstly, there is currently a lack of data on prevalence of HPV infection among the Swedish 
population which needs to be addressed. There are only limited data from the previous 
Swedescreen- study (1997-2000) targeting women between age 32 and 38.  
 
Further, primary HPV-based screening is gradually being introduced throughout Europe as in 
Sweden. Future research should within the preventive program confirm that HPV testing with 
triage cytology will increase detection of CIN2+ compared with conventional cytology alone, 
result in fewer follow-up procedures and less unnecessary treatment.  
 
There are concerns regarding recurrent disease in women diagnosed and treated for CIN2+. 
Among these women, Meta-analyses of previous studies indicate an increased risk of adverse 
birth-outcomes for women of fertile age. Cold-knife conization in particular was associated 
with increased risk of perinatal mortality, extreme preterm delivery and low birth weight. 
Future research should therefore focus on gathering data on the long-term effects of current 
treatment options for CIN. Women diagnosed with CIN are at higher risk of subsequent 
cervical cancer. Follow-up strategies appropriate for decreasing the risk of or development of 
cancer in these women should therefore be evaluated. These data should all be incorporated 
into cost-effectiveness studies to confirm the cost-effective combinations of screening 
including management and treatment of CIN, follow-up strategies and birth outcomes in 
order to minimize risks and maximize the health benefits of cervical cancer screening 
programs.  
 
Switching from current conventional cytology screening to HPV testing for primary 
screening has raised concern about possible low compliance with a 5-year screening interval 
after a HPV-negative test compared with the current 3-year interval following a negative 
cytology test. Currently, no studies have been published on compliance with the specified 5-
year interval after an HPV-negative test. Therefore, future research should be conducted on 
compliance with screening protocols, both in clinical trials and through register-based data. 
Another important subgroup in the new screening protocol using primary HPV-DNA testing 
relates to women who are HPV-positive and cytology negative. Previous studies have shown 
that such women prefer to be examined immediately with colposcopy. Future research should 
be performed on this subgroup to investigate barriers (induced anxiety, low awareness and 
knowledge of HPV, risk factors and their relationship to diseases) and facilitators (increased 
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awareness and knowledge of HPV) of compliance with screening protocols adjusted for this 
subgroup. 
 
In addition, the potential of infecting others with HPV may pose new problems with anxiety 
related to sexually transmitted diseases that are linked to development of any HPV related 
cancer. Research should also be conducted on effective communication tools for HPV-
positive women to reduce unnecessary colposcopies and biopsies, as well as overtreatment of 
regressive CIN, which is a risk if reassurance is not effectively communicated. 
  
Facilitators and barriers are related to knowledge and the ability to comprehend the message 
communicated by health professionals, which ultimately relates to educational level. Further 
research should therefore be carried out on correlates of compliance with screening protocols. 
Research should therefore focus on providing insights into effective communication tools 
about HPV, and how to reduce SES inequalities. 
 
Future research should consider the feasibility of HPV self-sampling devices for screening of 
the two most relevant subgroups: non-participants, hard-to-reach women. Furthermore, HPV 
self-sampling may reduce screening costs however further research on this is also needed. 
Equity of access to health care is a major concern. HPV self-sampling could potentially 
reduce inequity of access provided that the healthcare system can access all women through 
postal services. Concerns are about those women that cannot be reached at their home. 
Therefore, other ways to reach women such as pick up self-sampling devices at pharmacy or 
other local services should also be considered within the framework of the organized 
screening program and further Evaluated.  
 
This thesis explored annual costs in Sweden of the HPV-related diseases cervical cancer and 
genital warts. Our estimates were partly based on assumptions since there is little data 
concerning on epidemiology and costs linked to HPV related diseases in Sweden. To 
understand the societal costs of HPV-related diseases, proper cost-of-illness studies must be 
conducted in which detailed information on resource use and productivity is gathered 
concerning all major HPV-related diseases, including cervical dysplasia, invasive cervical 
cancer, genital warts, cancer of the vulva, vagina, anus, penis and head and neck and 
recurrent respiratory papillomatosis and any other diseases that may be linked to HPV in the 
future. How various HPV types relate to different diseases in terms of etiology and 
epidemiology also needs further investigation.  
 
In future generations, the upcoming nine valent vaccine is expected to prevent 90% of cases 
of invasive cervical cancer among HPV naïve women. Recent results from vaccine studies 
showed high vaccine efficacy against CIN2+ in women with serological evidence of past 
HPV infection but no active HPV infection at the time of vaccination. This suggests that 
these women who solely relays on screening as preventive method could potentially benefit 
from HPV vaccination in the future. However, until then, cervical cancer screening must 
continue since vaccination offers no protection against those HPV types not included in the 
first-generation vaccines. Since there will be a lower incidence of precancerous lesions and 
cervical cancer diseases as an effect of the HPV vaccination program, the current approach 
using frequent cytology-based screening will not be considered cost-effective. Therefore, 
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further research should focus on new alternative screening technologies and protocols for 
these subgroups. Also, future research should focus on the question whether to include boys 
into the vaccination programme.  As new data become available, cost-effectiveness analyses 
should be updated with vaccine-related parameters in order to confirm the preferable 
screening approach for both vaccinated and unvaccinated women. When replacing older 
interventions with new ones, decisions about allocations will have to be based on formal 
evaluations of the additional health benefit is worth the additional cost. 
 
In summary, all of the above mentioned suggestions for future research are crucial to 
maximize health benefits of screening, while minimizing the risks of women being over-
screened, over-diagnosed and consequently over-treated. All of the above suggestions can be 
followed up within existing national register-based data to prevent cervical cancer.   
 
  
 82 
8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Livmoderhalscancer är en angelägen fråga, både humanitärt och ekonomiskt för hela världen. 
Utifrån forskningen är det nu väl känt att livmoderhalscancer orsakas av Humant 
Papillomvirus (HPV), som är en sexuellt överförd infektion. HPV är den vanligaste sexuellt 
överförbara sjukdomen bland unga kvinnor och män runt om i världen. Detta gör 
livmoderhalscancer till den näst vanligast cancerformen bland kvinnor i världen, med knappt 
en halv miljon fall som upptäcks och omkring en kvarts miljon kvinnor som dör varje år i 
sjukdomen. Majoriteten av kvinnorna som drabbas bor i utvecklingsländer. I Sverige är det 
omkring 450 kvinnor som drabbas och 150 kvinnor dör varje år av livmoderhalscancer. Det 
finns olika typer av livmoderhalscancer, som utvecklas från olika celler. Den vanligaste är 
skivepitelcancer som står för omkring 80% av alla fallen. Fall av skivepitelcancer i 
livmoderhalsen har minskat dramatiskt under de senaste årtiondena i länder som infört 
organiserad screening med cellprov. Den andra typen är adenocarcinoma som utgör omkring 
ca 20 % av alla tumörer i livmoderhalsen och utgår från körtelepitelceller. Denna form är 
tyvärr inte lika lätt att upptäcka med cellprov som skivepitelcancer. Dessutom vet man inte 
lika mycket om dess orsaker, som man vet om skivepitelcancer. Följaktligen har 
livmoderhalscancer av körtelepiteltyp snarare ökat under det senaste årtiondet. Infektion med 
Humant papillomvirus (HPV) är nödvändig för att livmoderhalscancer ska utvecklas och i 
nästan 100% av alla fallen  återfinns HPV-16 och HPV-18, de vanligaste förekommande hög 
risk typerna. HPV är mycket vanligt förekommande bland både män och kvinnor och smittar 
vid sexuell kontakt. Den diagnostik som bedrivs med cellprovet är otillräckligt och därför blir 
kvinnorna idag inte sällan föremål för onödig gynekologisk utredning och överbehandling 
vilket i förlängningen kan påverka kvinnans psykiska och fysiska hälsa. HPV test är 
bevisligen mer effektiva än cellprovet att upptäcka förstadier till livmoderhalscancer. En 
förbättrad diagnostik med HPV test skulle kunna öka möjligheten att upptäcka kvinnor som 
riskerar att utveckla livmoderhalscancer i tidigare skede. 
I Sverige, med ett omfattande organiserad screeningprogram med cellprov har man sedan 
2012 kompletterat preventionsarbetet med det allmänna vaccinationsprogrammet med HPV-
vaccinering av 11-åriga flickor för att ytterligare minska antalet fall av livmoderhalscancer i 
framtida generationer. Vaccinet som används idag skyddar mot två högrisktyper-HPV 16 och 
HPV 18 som är klart dominerande när det gäller risk att utveckla cervixcancer men skyddar 
endast upp till 70% av fallen. Fortfarande finns det behov av screening för att kunna ge ett 
effektivt skydd mot livmoderhalscancer hos hela den kvinnliga befolkningen.  
Vidare skyddar vaccinet mot HPV 6 och HPV 11 som orsakar kondylom. Kondylom utgör en 
av de vanligaste könssjukdomarna bland främst unga män och kvinnor. Sjukdomen utvecklar 
ofarliga vårtor i underlivet eller kring ändtarmsöppningen. Trots att vårtorna är ofarliga kan 
de orsaka klåda, sveda, små blödningar och besvär vid samlag. I en tidigare studie 
uppskattades att omkring 20 000 nya fall av kondylom behandlas medicinsk varje år. Detta 
sammantaget gör även kondylom till en angelägen fråga, både humanitärt och ekonomiskt. 
Utifrån tidigare forskningsresultat förväntas antalet fall minska bland unga upp till omkring 
80 % med införandet av HPV vaccinet.  
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Hälsoekonomi är ett område, inom vilket man analyserar hälsa och sjukvård utifrån 
ekonomisk teori och empiri, och med metoder som specifikt utvecklats för området. Syftet 
med hälsoekonomiska utvärderingar är att estimera de hälsoeffekter och kostnader som 
uppkommer vid införande av nya interventioner, behandlingar, teknologier eller läkemedel. 
Det är oundvikligt att val mellan tillgängliga alternativ måste göras då det alltid finnas mer 
alternativ än samhällets resurser tillåter. Besluten om allokering av resurser och byta ut gamla 
interventioner mot nya ska baseras på formella utvärderingar om den extra hälsoeffekten är 
värd den extra kostnaden för samhället.  
Europeiska kommissionen ger rekommendationer om screening för livmoderhals-, bröst- 
samt kolorektalcancer som inte är bindande, men policypåverkande för samtliga europeiska 
länder. Inom EU utformas även HTA-analyser (”Health Technology Assessment”) för 
screening (EUnetHTA)och implementeringsprogram (European Partnership for Action 
Against Cancer – EPAAC). 
Enligt Socialstyrelsen i Sverige ska screening program för cancer uppfylla kraven på att vara 
både kliniskt effektiva och kostnadseffektiva innan beslut kan tas om introduktion av 
nyascreening program eller förändringar av befintliga. För att ett screening program ska 
kunna uppfylla dessa krav krävs det också att kvinnorna accepterar screening programmets 
utformning och går på kontrollerna enligt kallelse. Det är därför viktigt att identifiera 
potentiella barriärer till hörsamhet och deltagande i screening program. Utifrån den 
teknologiska utvecklingen av nya och idag tillgängliga HPV tester som bevisligen är mer 
effektiva än cellprov för att upptäcka förstadier av livmoderhalscancer pågår en översyn av 
det nationella screening programmet för livmoderhalscancer. Arbetet ska vidare leda till 
beslut om användande av HPV tester istället för dagens cellprov i screening programmet.    
Målet med denna avhandling var att undersöka kostnaden för livmoderhalscancer och 
undersöka vilken screening metod som potentiellt kan vara kostnadseffektiv (i.e. screening 
med cellprov i jämförelse med HPV test) och identifiera potentiella barriärer till kvinnors 
deltagande i screening programmet.  
I det första delarbetet undersökte vi utifrån ett hälso- och sjukvårds perspektiv om HPV test 
var ett kostnadseffektivt alternativ i jämförelse med cellprovet eller en omedelbar 
undersökning av livmoderstappen i mikroskop med riktade vävnadsprov som uppföljning av 
kvinnor som hade lindriga cellförändringar vid första screening tillfället. Resultatet visade att 
omedelbar mikroskopi (kolposkopi) och riktade vävnadsprov var en kostnadseffektiv 
uppföljningsmetod i jämförelse med både cellprovet och HPV testet för att upptäcka måttliga 
tillstarka cellförändringar. Detta beroende till stor del på att uppföljning med endast cellprov 
eller HPV test är mindre effektiva metoder som leder till ytterligare gynekologisk uppföljning 
vid upptäckt av cellförändringar eller hög-risk HPV och därmed även högre kostnader. Direkt 
kolposkopi och vävnads prov har högre effektivitet och utgör endast en kostnad för ett besök 
hos läkare för diagnos innan beslut om behandling. Studien gjordes när cytologiska prover 
med Pap smear utgjorde större andelen av cellproverna i Sverige. Idag används mestadels 
vätskebaserad cytologi som möjliggör efterföljande HPV test ur samma prov. HPV testning i 
kombination med vätskebaserad cytologi (s.k. HPV-reflex) skulle istället kunna utgöra ett 
kostnadseffektivt alternativ. 
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I den andra studien undersökte vi utifrån ett samhällsperspektiv och inom ramen av det 
organiserade screening programmet om en kombinationsstrategi med cellprov hos kvinnor 
mellan 23 och upp till 35 år och därefter HPV-självtest till 60 års ålder var ett 
kostnadseffektivt alternativ till cellprovet. Resultatet visade att kombinationsstrategin var ett 
kostnadseffektivt alternativ i jämförelse med cellprovet och ingen screening. 
 I tredje studien undersöktes kostnader i samband med ett besök för cellprov, kännedom om 
HPV och deltagande i screeningen. Resultatet visade på en hög kostnad för 
produktionsbortfall och andra kostnader för resa, transport, barnvakt etc. som uppstår när 
kvinnan deltar i screeningen. Vidare svarade 53 % av kvinnorna att de tagit ledigt från arbetet 
för att deltaga i screeningen varav 44% angav att de inte deltar i screeningen inom 1 år från 
den första kallelsen pga. sin arbetets situation. Generellt hade kvinnorna låg kännedom om 
HPV och endast 34% kände till att det var viktigt att fortsätta gå på kontroller efter HPV 
vaccination. Kvinnor som uppgav att de tog ledigt från arbetet för att delta var mindre 
benägna att delta i screeningen inom 1 år från kallelsen. De kvinnor som hade låg kännedom 
om HPV deltog inte heller i lika stor utsträckning som de med högre kännedom om HPV. 
Viktigt var också att kvinnor med låg SES var mindre representerade bland deltagarna.    
I fjärde delstudien undersökte vi utifrån ett samhällsperspektiv kostnaderna för prevention, 
diagnostik och behandling av förstadier och utvecklad livmoderhalscancer tillsammans med 
kostnaderna för behandling av kondylom i Sverige.  Samhällets kostnad innan initiering av 
organiserad HPV vaccinering av flickor uppskattades till omkring 108 miljoner Euro. 
Kostnaden för screening uppgick till omkring 77% av den totala kostnaden för 
livmoderhalscancer.  
Fortfarande finns bristande kunskap om HPV relaterade sjukdomar och om framtida 
förebyggande strategier (exempelvis vaccination) som prevention vid dessa cancerformer. 
Vidare är prevalensen av HPV infektioner inom den svenska befolkningen är fortfarande 
okänd. Det finns endast data från Swedescreen-studien (1997-2000) för en begränsad 
åldersgrupp. Det saknas även svensk data om riskerna för att barn föd förtidigt efter 
behandling av dysplasier med konisering. Det saknas också information om kvinnors 
inställning till HPV-test jämfört med det traditionella cellprovet, detta oavsett om det tas på 
den lokala mödravårdscentralen eller om det tas av kvinnan själv i hemmet (s.k. HPV-
självtest). Vidare saknas information om hur kvinnor uppfattar ett besked från sjukvården 
om att de är HPV-positiva. Frågor som också bör besvaras är hur kvinnor som är HPV-
positiva med normal cytologi och HPV-vaccinerade ska följas upp i screening 
programmet. När HPV test införs i det screening programmet istället för cellprovet bör 
även effekten av införandet på kvinnors deltagande följas upp. Även användandet av HPV 
självtest bör följas upp inom screening programmet. Mycket av ovanstående 
kunskapsluckor kan följas upp i det nationella kvalitetsregistret för förebyggande av 
livmoderhalscancer.  
En annan väldigt viktig fråga som bör utredas är om även pojkar ska erbjudas HPV 
vaccination. Det är för tidigt att säga om och i vilken grad en allmän HPV-vaccination av 
både flickor och pojkar skulle påverka flockimmuniteten mot HPV relaterade 
cancersjukdomar. Skyddseffekten av HPV-vaccin hos pojkar utvärderas i takt med att nya 
forskningsresultat blir tillgängliga. Men redan idag visar forskningsresultaten alltmer på att 
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HPV förekommer även i andra tumörformer som t ex huvud–halscancer och anogenitala 
tumörer. Man vet att HPV 16 spelar en viktig roll för ökningen av tonsillcancer som tros 
öka det närmsta årtiondet och speciellt bland unga män som idag står utanför 
barnvaccinationsprogrammet. En omprövning av om även pojkar ska vaccineras bör ske 
inom kort för att stävja en vidare ökning. 
Sammantaget utgör denna avhandling information inför vidare beslut om förändring av 
befintligt nationellt screening program för livmoderhalscancer. 
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